Molecular, immunological and genetic studies on murine autoimmune pancreatitis by Asghari, Farahnaz (gnd: 1079150099)
 
 
 
 
 
 
MOLECULAR, IMMUNOLOGICAL AND GENETIC STUDIES 
ON  
MURINE AUTOIMMUNE PANCREATITIS 
 
 
 
 
 
Dissertation 
zur 
Erlangung des akademischen Grades 
doctor rerum naturalium (Dr. rer. nat.) 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Universität Rostock 
 
 
Vorgelegt von: 
 
Farahnaz Asghari, M.Sc. 
geboren am 08.12.1967 in Hashtrood (Iran) 
 
 
Rostock 
 
2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gutachter: 
1.Gutachter:  
           Prof. Dr. med. Robert Jaster 
           Klinik für Innere Medizin II 
           Abteilung Gastroenterologie und Endokrinologie,  
           Universitätsmedizin Rostock 
 
2.Gutachter:  
           Prof. Dr. Ulrike Gimsa 
         Leibniz-Institut für Nutztierbiologie 
           Institut für Verhaltensphysiologie, Dummerstorf 
 
 
Datum der Einreichung:     12. Januar 2015 
Datum der Verteidigung:    03. Juli 2015 
 
 
 
 
Contents 
 
1	   Introduction 1	  
1.1	   Autoimmunity 1	  
1.2	   Autoimmune Diseases (AID) 1	  
1.2.1	   Autoimmune Pancreatitis (AIP) 2	  
1.2.1.1	   General Aspect of Autoimmune Pancreatitis 2	  
1.2.1.2	   Epidemiology 7	  
1.2.1.3	   Diagnosis 7	  
1.2.1.4	   Treatment 8	  
1.2.1.5	   Environmental Risk Factors 10	  
1.2.1.6	   Genetics of CP and AIP 10	  
1.2.1.7	   Mouse Models of AIP 11	  
1.3	   Strategies to Identify Susceptibility Genes of Complex Diseases 15	  
1.3.1	   From Disease to Quantitative Trait Loci by Linkage Analysis 15	  
1.3.2	   QTLs Mapping 16	  
1.3.3	   Identification of Susceptibility QTL of AIP in Four-way AIL 17	  
1.4	   Aims of This Study 18	  
2	   Materials and Methods 19	  
2.1	   Materials 19	  
2.1.1	   Instrument & Laboratory supplies 19	  
2.1.2	   Commercial kits 19	  
2.1.3	   Chemical and Reagents 20	  
2.1.4	   Antibodies 20	  
2.1.5	   Buffers and Solutions 21	  
2.1.6	   Mice 22	  
2.1.6.1	   Generation of Four-way Autoimmune Advanced Intercross Line (AIL) 22	  
2.1.6.2	   The Fourth Generation (G4) of Four-way AIL Mice 23	  
2.2	   Methods 24	  
2.2.1	   Protocol for AIP and Autoimmune Diseases Studies 24	  
2.2.1.1	   Sacrificing and Sampling 24	  
2.2.1.2	   Spontaneous AIP 26	  
2.2.2	   Molecular Biological Methods 29	  
2.2.2.1	   Isolation of Mouse Total DNA 29	  
2.2.2.2	   Quantitative Trait Loci (QTLs) Identification 29	  
2.2.2.3	   QTL Mapping 29	  
2.2.3	   Immunological Methods 30	  
2.2.3.1	   Flow Cytometry 30	  
2.2.3.2	   Cells Subpopulation Determination 33	  
2.2.4	   Statistical Analysis 34	  
3	   Results 35	  
3.1	   Phenotyping Analysis of 4-way Autoimmune-prone Intercross Mouse Line 35	  
3.2	   Identification of Quantitative Trait Loci for Spontaneous AIP 37	  
3.3	   Selected Candidate Genes 39	  
3.4	   AIP QTLs Overlap with QTLs for Other Autoimmune Diseases 43	  
3.5	   Detection of Immune Response Phenotypes 44	  
4	   Discussion 53	  
4.1	   Four-ways Autoimmune-prone Advanced Intercross Line (AIL) Progeny 54	  
4.2	   Development of AIP 54	  
4.3	   QTL Analysis 55	  
4.3.1	   AIP1 QTL and Its Candidate Genes 56	  
 
 
4.3.1.1	   Heterogeneous Nuclear Ribonucleoprotein A3 Gene (Hnrnpa3) 57	  
4.3.1.2	   Nuclear Factor, Erythroid Derived 2, Like 2 Gene (Nfe2l2; Nrf2) 58	  
4.3.1.3	   Sjogren´s Syndrome Antigen B Gene (Ssb) 58	  
4.3.1.4	   Ubiquitin Protein Ligase E3 Component n-Recognin 3 Gene (Ubr3) 59	  
4.3.2	   AIP5 QTL 59	  
4.3.2.1	   C-type Lectin Domain Family 4, Member a2 Gene (Clec4a2) 60	  
4.3.2.2	   Peroxisome Proliferator Activated Receptor Gamma Gene (Pparg, PPARγ)
 61	  
4.3.3	   AIP2 QTL 61	  
4.3.3.1	   Autoimmune Aoritis in MRL Mice 1 (Aaom1) 62	  
4.3.3.2	   Lupus BXSB x NZW 1 (Lxw1) 62	  
4.3.4	   AIP3 QTL 63	  
4.3.4.1	   Systemic Lupus Erythematosus Susceptibility 2 (Sle 2) 63	  
4.3.4.2	   Anti-dsDNA Antibody Production in NZM 1(Adaz1) 63	  
4.3.4.3	   Autoimmune Glomerulonephritis in MRL 2 (Agnm2) 63	  
4.3.4.4	   Proteoglycan Induced Arthritis 27 (Pgia27) 64	  
4.3.4.5	   Psoriasis-like Skin Disease Severity 1(Psds1) 65	  
4.3.5	   AIP4 QTL 65	  
4.3.5.1	   Cytokine Deficiency Colitis Susceptibility 10 (Cdcs10) 65	  
4.4	   Pathogenesis of AIP in G4 Mice 66	  
4.4.1	   AIP1 QTL and Immune Cell Phenotypes 67	  
4.4.2	   Effect of AIP QTLs on Th1/Th2-type Cellular Immune Response 70	  
4.4.3	   T helper 17 (Th17) and AIP 71	  
5	   Conclusions 74	  
6	   Summary 75	  
7	   Zusammenfassung 77	  
8	   References 79	  
9	   Appendix 95	  
9.1	   Abbreviations I	  
9.2	   List of Figures VII	  
9.3	   List of Tables VIII	  
10	   Acknowledgements IX	  
11	   Curriculum Vitae XI	  
12	   Statements XII	  
 
 
 
 Introduction  
1 
 
 
1 Introduction 
1.1 Autoimmunity 
The key role of the immune system is to distinguish self-antigens (autologous) from 
foreign agents such as bacteria, viruses or various environmental factors that are recognised as 
non-self (pathogens). Immune system reacts specifically against pathogens but acquires self-
tolerance to autologous antigens. Tolerance to self-antigens is acquired through several 
distinct regulatory mechanisms such as clonal deletion of auto-reactive T clones in the thymus 
during the prenatal period or functional suppression of auto-reactive T and B clones at later 
stages of the development of the organism (anergy, ignorance and suppression). A failure to 
distinguish ‘self’ from ‘non-self’ may lead to an autoimmune response, which is characterised 
by activation and clonal expansion of autoreactive T and B-lymphocytes, and production of 
autoantibodies. This in turn results in inflammation, tissue injury and subsequent development 
of autoimmune diseases, such diabetes mellitus type1, Graves' disease, Hashimoto's 
thyroiditis, Idiopathic Thrombocytopenic Purpura (ITP), Rheumatoid Arthritis (RA), Sjögren's 
syndrome, Systemic Lupus Erythematosus (SLE) and autoimmune pancreatitis (AIP). 
1.2 Autoimmune Diseases (AID) 
Autoimmune diseases can be classified into two distinct groups: organ specific 
(localised) and non-organ specific (systemic autoimmune disorders). The effects of systemic 
autoimmune diseases present throughout the entire body, i.e. commonly showing 
inflammation in joints, muscles and organs. The prevalence of autoimmune disorders is 
particularly reported in Europe and the USA. The National Institute of Health (NIH) estimated 
approximately 14.7-23.5 million Americans to be affected with at least one autoimmune 
condition (Autoimmune Diseases Coordinating, 2005). According to the American 
Autoimmune Related Diseases Association (AARDA), it has been estimated that 
approximately 50 million people are affected with AID in the United States (Schmidt, 2011), 
of which 75% are women. Based on these reports, the incidence of autoimmune diseases is 
8% in the USA population (Autoimmune Diseases Coordinating, 2005) and from 3-5% 
worldwide (Jacobson et al., 1997; Maas et al., 2002; Marrack et al., 2001) therefore, further 
indicating that the prevalence of AID had extremely increased over the past few years. 
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The susceptibility to complex diseases, such as autoimmune and chronic inflammatory 
disorders is known to be controlled by genes, environmental factors, or interaction between 
both (Bang et al., 2010; Franke et al., 2010; Han et al., 2009; Naldi et al., 2005). Over the last 
decade the genetic basis of many autoimmune diseases have been extensively studied 
(Fernando et al., 2008). 
1.2.1 Autoimmune Pancreatitis (AIP) 
1.2.1.1 General Aspect of Autoimmune Pancreatitis 
Chronic pancreatitis (CP) is a relapsing inflammatory disease that leads to permanent 
degeneration, exocrine-endocrine dysfunction of the pancreas, and an increased risk of 
pancreatic cancer (Etemad & Whitcomb, 2001). Auto-digestive reactions including secretion 
of pancreatic proteases and subsequent regenerative processes, play a pivotal role in the 
pathogenesis of the disease (Klöppel & Maillet, 1993). The major risk factor for developing 
CP includes alcohol abuse. However, biliary diseases and genetic defects are also known to be 
a common cause of CP. Interestingly, in up to one third of the cases, the cause of CP remains 
unknown. Chronic pancreatitis usually develops in adults aged 40 to 50 and it predominantly 
affects more men than women (Etemad & Whitcomb, 2001). It has been previously reported 
that alcoholic pancreatitis is the most common type of CP in males, while idiopathic 
pancreatitis is reported to affect predominantly females (Lin et al., 2000). Despite on the 
growing knowledge in field, the treatment of CP remains challenging in vast majority of the 
cases. 
AIP is a rare cause of chronic pancreatitis that was recognized as a clinical entity in the 
last decades. The first description of chronic pancreatitis with sclerosis as an autoimmune 
condition was published in 1961 (Sarles et al., 1961). Thirty years later Kawaguchi reported 
two cases of unusual inflammatory disease involving pancreas and biliary tract and described 
it as a lymphoplasmacytic sclerosing pancreatitis (LPSP) (Kawaguchi et al., 1991). However, 
the original term of “autoimmune pancreatitis” was proposed only later by Yoshida et al. 
(Yoshida et al., 1995). According to a study performed in a regional cohort of 545 CP patients 
with, the percentage of AIP in all forms of CP is approximately 10% (Schneider & Löhr, 
2009). 
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Occasionally, AIP is associated with other autoimmune diseases, primarily the Sjögren’s 
syndrome (Kamisawa, Funata, Hayashi, Tsuruta et al., 2003; Pickartz et al., 2004). 
Histopathologically, AIP is characterised by a periductal inflammatory cell infiltration, 
followed by an obliterative periductal fibrosis (Klimstra & Adsay, 2004). In severe cases, the 
inflammation includes pancreatic acini, which lead to the loss of lobular pancreatic 
architecture. Both inflammation and fibrosis may result in the formation of an inflammatory 
pseudotumour (Klöppel et al., 2003) and cause obstructive jaundice, thus making the 
differential diagnosis between AIP and pancreatic carcinoma difficult. As a result, up to 10% 
of patients who undergo surgical resection for a suspected pancreatic cancer have a final 
diagnosis of pancreatitis (Wolfson et al., 2005). Usually AIP patients respond well to 
corticosteroid therapy, whereas the application of steroids is ineffective in more common 
forms of CP (Kojima et al., 2003; Song et al., 2005). 
One of the key features of AIP are elevated IgG4 levels in AIP patients sera (Wang et 
al., 2013). Over the last years, the variable sensitivity of IgG4 levels in the sera of the patients 
(from 70% to 90.9%) was proposed as a diagnostic marker for classification of AIP into its 
distinct subtypes, AIP 1 and 2. Moreover, high concentrations of IgG4 in patients serum 
provided a useful tool for differential diagnosis of sclerosing pancreatitis from other diseases 
of the pancreas or biliary tract (Hamano et al., 2001). Despite the identification of 
autoantibodies in AIP, IgG4 sera content is still not considered as a specific diagnostic marker 
(Frulloni et al., 2009). Hence, more sensitive and specific markers for diagnosis of AIP are 
required. 
To date, the first diagnostic criteria for AIP were issued by the Japan pancreas society 
(JPS) in 2002. During last decade, at least eight sets of diagnostic criteria of AIP have been 
proposed (Otsuki et al., 2008). However, the criteria summarized as “HISORt” and “The Final 
Asian Criteria” are currently the main criteria for the diagnosis of AIP (Chari, 2007; Divatia et 
al., 2012). 
Mayo clinic diagnostic criteria for autoimmune pancreatitis summarised as HISORt 
(Chari, 2007) and are based on the following five cardinal features: 
• Histology: at least one of the following features: Lymphoplasmacytic infiltrate 
with storiform fibrosis and obliterative phlebitis (LPSP) or LPSP abundant 
IgG4 cells (≥ 10 IgG4 cells/ HPF)1 
                                                
1 HPF; per high power field 
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• Imaging: “sausage-shaped” enlargement of the gland on a computerized 
tomography (CT) scan and magnetic resonance imaging (MRI) 
• Serology: elevated titers of gammaglobulins (IgG) 2, elevated serum levels of 
the IgG4 and a variety of antibodies including antinuclear antibody, rheumatoid 
factor, carbonic anhydrase, and lactoferrin 
• Other organ involvement: biliary ductal system, salivary glands and 
retroperitoneum 
• Response to steroid therapy 
Considering these criteria, AIP should be suspected in patients with obstructive 
jaundice, pancreatic mass/enlargement or pancreatitis, and patients who exhibit one or more of 
these five cardinal features. 
The Final Asian AIP diagnostic criteria were obtained at the third Japan–Korea 
symposium on AIP in 2008, based on following features: 
I: Imaging (both required): a: enlargement of the gland (diffuse/ segmental/ focal) 
occasionally with a mass and/or a hypo-attenuation rim, b: pancreatic duct narrowing (diffuse/ 
segmental/ focal) often with stenosis of the bile duct. 
II: Serology (one required): elevated serum IgG/ IgG4 and detectable autoantibodies 
(ANA; Anti-nuclear antibody and RF; Rheumatoid factor). 
III: Histopathology: lymphoplasmacytic infiltration (IgG4 positive) with fibrosis. 
It has been proposed that AIP should be diagnosed when criterion I (Ia and Ib) and one 
of the other two criteria II or III are fulfilled (Criterion I+II, Criterion I+III, Criterion I+II+III) 
or when lymphoplasmacytic sclerosing pancreatitis in the resected pancreas is observed 
(Otsuki et al., 2008). 
International consensus diagnostic criteria (ICDC) were developed for diagnosis of 
both subtypes of AIP separately. The combination of one or more of following five cardinal 
features; namely, imaging of pancreatic parenchyma and duct, serology, other organ 
involvement, pancreatic histology and an optional criterion of response to steroid therapy 
could be used to confirm AIP diagnosis. Each feature was classified into level 1 and 2 based 
on the diagnostic reliability (Otsuki et al., 2008; Park, Chung et al., 2008). 
                                                
2 Ig stands for immunoglobulin 
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Recently, the diagnostic criteria for AIP were expanded due to the accumulation of 
clinical experience, development of newer diagnostic methods and changes in the concept of 
AIP. The differentiation of AIP from pancreatic cancer is extremely important. In this regard, 
there is a need to update the criteria continuously and to develop unified criteria, which would 
be shared worldwide. In accordance with this purpose, Ebbo et al. reviewed the 
pathophysiological hypothesis and therapeutic approaches of IgG4-RSD and suggested that 
there is still no international validated diagnostic criteria for IgG4-RSD (Ebbo et al., 2012). 
Most of autoimmune pancreatitis cases have been reported from Japan, Europe and the 
US. The disease descriptions from Japan have been based mainly on the existence of different 
clinical phenotypes. On the other hand, reports from Europe and the USA described at least 
two distinct histopathological patterns found in AIP patients; lymphoplasmacytic sclerosing 
pancreatitis (LPSP; type 1); and idiopathic duct-centric pancreatitis (IDCP; type 2) or 
granulocytic epithelial lesion (GEL)-positive pancreatitis. The two subtypes can be 
distinguished by their development of extrapancreatic manifestations, namely periductal 
lymphoplasmacytic infiltration and peculiar periductal fibrosis(Chari et al., 2010; Okazaki et 
al., 2010). The characteristic findings of type AIP type1 are sufficient infiltration of pancreatic 
tissue by IgG4+ plasma cells and lymphocytes (Masaki et al., 2011), storiform fibrosis, 
association with non-specific autoantibodies and elevated serum IgG4/IgE levels. In addition, 
these patients often show extrapancreatic lesions such as sclerosing cholangitis, sclerosing 
sialadenitis, or retroperitoneal fibrosis with similar pathological features. Based on these 
findings, some synonyms were suggested for the same condition, namely “multifocal 
idiopathic fibrosclerosis”, “IgG4-related autoimmune disease”, “IgG4-related sclerosing 
disease”, “IgG4-related plasmacytic disease”, and “IgG4-related multiorgan 
lymphoproliferative syndrome” (Kamisawa, Funata, Hayashi, Tsuruta et al., 2003; Ketwaroo 
& Sheth, 2013; Okazaki et al., 2011; L. Zhang & Smyrk, 2010). As opposed to AIP type 1, 
AIP type 2 is predominantly characterised by granulocytic epithelial lesions, which are 
frequently associated with a destruction and obliteration of the pancreatic duct. Moreover, no 
elevated IgG4 levels and infiltrates of IgG4-positive plasma cells were observed in the sera of 
patients suffering from AIP type 2 (Table 1.1). Finally, an association between inflammatory 
bowel disease and AIP type 2 has been also previously described (Okazaki et al., 2010). Up to 
date, the study of pathogenesis of the different subtypes of AIP in mice remains difficult due 
to the lack of IgG4 in mice. Nevertheless, the presence of nonspecific autoantibodies in the 
serum and the histology of the pancreas, specifically the absence of granulocyte epithelial 
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lesions in the pancreatic ducts and acini are just some of the evidence that show that MRL/Mp 
mouse is a good model to study the human AIP type 1. 
 
Table 1.1 Comparison of type1 and type2 autoimmune pancreatitis (AIP) 
 Type 1 AIP Type 2 AIP 
Synonym Lymphoplasmacytic sclerosing 
pancreatitis 
AIP without GEL 
Idiopathic duct-centric 
chronic pancreatitis 
AIP with GEL 
Epidemiology Asia˃ USA, Europe Europe˃ USA˃ Asia 
Age at diagnosis Old Young (Child and adult ) 
Gender predominantly  Male predominance Almost equal or small 
difference 
Clinical presentation Obstructive jaundice (painless) Obstructive jaundice 
(painless), abdominal 
pain/acute pancreatitis 
Serum IgG4 levels  Often Elevated  Normal 
Other organ involvement  Gland, kidney, retoperitoneum Not seen  
Histological nomenclature  Lymphoplasmacytic  
sclerosing pancreatitis 
Idiopathic duct-centric  
Pancreatitis 
Ducts 
 
Periductal inflammation  
Preserved epithelium 
Intraepithelial neutrophils  
damaged epithelium 
Lobule Lymphoplasmacytic 
inflammation with storiform 
fibrosis 
Patchy inflammation, often 
with neutrophils 
Veins  Phlebitis very common Phlebitis unusual  
IgG4+ plasma cells  Many  Rare 
Extra-pancreatic lesions  IgG4-RD Inflammatory bowel disease 
Granulocytic epithelial 
lesion  
Absent  Present 
Association with 
ulcerative colitis 
Occasionally Common 
Steroid responsiveness Excellent Excellent 
Relapse rate  High  Low 
AIP, autoimmune pancreatitis; GEL, granulocytic epithelial lesion; IgG4-RD, IgG4-related disease. 
Adopted from (Kamisawa et al., 2013; Okazaki et al., 2011; Park et al., 2009; Wang et al., 2013). 
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1.2.1.2 Epidemiology 
The prevalence of autoimmune pancreatitis (AIP) is reported regularly from Japan, 
Europe and the USA (Chari et al., 2010). Although recent worldwide reports show that the 
incidence and the prevalence of autoimmune diseases are rising (Wang et al., 2013), the 
prevalence of AIP in the world remains unknown. Recent data showed that the prevalence and 
the incidence of AIP in Japan is 2.2 and 0.9 cases per 100,000 population, respectively (Kanno 
et al., 2012). AIP type I predominantly affects male patients with a male/female ratio of 2-5:1 
in Japan and 2:1 in Europe (Okazaki et al., 2005) whereas type 2 AIP shows no male 
predominance (Kamisawa et al., 2013). The age at diagnosis is 60-70 years in patients with 
type 1 AIP, and 50-60 in patients with type 2 AIP (Chari et al., 2010; Detlefsen et al., 2011; 
Nishimori et al., 2007; Okazaki et al., 2010). 
1.2.1.3 Diagnosis  
1.2.1.3.1 Clinical Manifestations 
AIP is identified incidentally, because patients show no symptoms or only have mild 
symptoms and usually without acute attacks of pancreatitis. The most common clinical 
manifestation in AIP patients is obstructive jaundice with little or no abdominal pain, whereas 
abdominal pain and elevated serum pancreatic enzymes are frequently observed in type 2 AIP 
(Kamisawa, Chari et al., 2011). The main symptom of other forms of CP is severe acute pain 
attacks, which is rather rare in AIP. A severe abdominal pain, pancreatic calcification and 
cysts are also rare in AIP patients. The common characteristic findings in AIP are elevated 
serum gammaglobulin IgG/ IgG4, presence of autoantibodies, diffuse enlargement of the 
pancreas, diffusely irregular narrowing of the main pancreatic duct, fibrotic changes with 
lymphocyte infiltration, occasional association with other autoimmune diseases and effective 
steroid therapy (Okazaki & Chiba, 2002). AIP, as a multi-organ disorder, presents both 
pancreatic and extrapancreatic features. Several extrapancreatic lesions that were reported in 
AIP patients are sclerosing cholangitis, sclerosing sialadenitis and retroperitoneal fibrosis. 
Pancreatic exocrine or endocrine malfunction in AIP, leads to diabetes mellitus (DM) or 
diabetes and steatorrhoea (Kamisawa et al., 2013; Okazaki, 2005). It has been reported that 
patients with AIP had DM prior to AIP or develop it simultaneously with AIP (Kamisawa, 
Egawa et al., 2003). AIP patients may show some symptoms that are associated to other 
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diseases, such as impaired glucose tolerance in patients with DM (Wang et al., 2013). The 
manifestations of AIP are versatile in both subtypes of AIP and are summarised in Table 1.1. 
1.2.1.3.2 Pathology 
Different pathological features of type 1 and type 2 AIP are more important for the 
diagnosis than an elevated serum IgG4 concentration. Pathological findings in type 1 AIP are 
IgG4-positive plasma cells and T-lymphocytes infiltration, storiform fibrosis, obliterative 
phlebitis and eosinophil infiltration, whereas neutrophilic infiltration in or around the 
pancreatic duct, duct destruction and rare obliterative phlebitis are common in type 2 AIP 
(Kamisawa et al., 2012; Wang et al., 2013). 
1.2.1.3.3 Laboratory Findings 
The characteristic laboratory findings in patients with AIP are: elevated serum 
gammaglobulin IgG/ IgG4, presence of auto-antibodies, increased hepatobiliray or pancreatic 
enzymes and impaired exocrine, and endocrine function of pancreas (Okazaki et al., 2005). 
Elevated serum pancreatic enzymes, namely lipase and amylase are detected in AIP type 2 
patients (Aughsteen et al., 2005; Tran et al., 2012). Although elevated serum IgG4 
concentration has been reported in most patients with AIP type 1, it is not a specific diagnostic 
marker for AIP (Strehl et al., 2011). 
Several AIP-related autoantibodies have been reported in AIP patients, such as anti-
lactoferrin (Okazaki et al., 2000), anti-carbonic anhydrase-II/IV (Aparisi et al., 2005; 
Nishimori et al., 2005), anti-pancreatic secretory trypsin inhibitor (Asada et al., 2006), anti-
amylasealpha (Endo et al., 2009), autoantibodies against the plasminogen-binding protein 
(Frulloni et al., 2009). However, the clinical significance of the aforementioned antibodies in 
AIP remains elusive and there is still a need for more sensitive and specific markers to 
diagnose the disease. 
1.2.1.4 Treatment 
Steroid therapy (as a standard therapy) is clinically, morphologically and serologically 
effective for AIP patients regardless of their subtypes (Kamisawa et al., 2012; Kamisawa, 
Takuma et al., 2011). The main goal of steroid therapy in AIP is to induce remission. Various 
regimens of steroids are available, but their dosage and duration in the acute phase of AIP are 
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still debated. Kamisawa et al. reported that AIP patients who received steroid treatment have 
shown significantly higher remission and lower relapse rates than the control group 
(Kamisawa et al., 2009). Both subtypes of AIP respond well to glucocorticoid therapy 
(Shinagare et al., 2012), but relapse rate is significantly higher in type 1 AIP than in type 2 
AIP patients (Detlefsen et al., 2011; Notohara et al., 2003). Predominantly, the response to 
therapy is defined by resolution of symptoms and radiological abnormalities as well as 
improvement in clinical and biomedical parameters (Ketwaroo & Sheth, 2013). Interestingly, 
splenomegaly in AIP patients was minimized after steroid therapy (Matsubayashi et al., 2013). 
Ordinarily, pancreatic function and morphologic characteristics return to normal within 4-6 
weeks, whereas serological and radiological remissions require more time (Vlachou et al., 
2011). 
AIP patients who relapse during maintenance steroid therapy or after stopping steroid 
medication should be re-treated with a high-dose steroid (Kamisawa & Okamoto, 2007). 
Immunosuppressive therapy and biological agents are the alternative treatments for the 
patients with recurrent or refractory AIP. Immunosuppressive components such as 
Azathioprine, 6-Mercaptopurine (Ghazale et al., 2008), Mycophenolate mofetil (Boehm & 
Bieber, 2001; Pisoni et al., 2005) and Cyclophosphamide (Brodsky, 2002) have been 
examined besides or instead of steroid therapy. However, data about their efficacy and 
treatment course are limited (Ketwaroo & Sheth, 2013). Similar to AIP patients, MRL/Mp 
mice respond well to steroid therapy. In addition to steroids, alternative immunosuppressant 
agents such as “Rapamycin” and “Cyclosporine A” are effective in treatment of murine AIP 
(Schwaiger et al., 2013). Considering the key role of autoreactive T cells in the pathogenesis 
of AIP in the MRL/Mp mouse model, “Cyclosporine A” and “Rapamycin” were suggested as 
a new treatment of AIP in humans (Schwaiger et al., 2013). Using biological agents, namely 
B-cell depletion with Rituximab, could be a promising treatment in patients with IgG4- related 
systemic disease (IgG4-RSD), who have shown recurrent or prove refractory to conventional 
immunosuppressive therapy (Khosroshahi et al., 2010). Even Bortezomib, a proteasome 
inhibitor, is a successful therapy for IgG4-RD (Khosroshahi & Stone, 2011) but it’s efficacy 
for treating AIP is unforeseeable (Wang et al., 2013). 
As the treatment options of AIP are currently limited and disease relapse is frequent, 
Seleznik et al proposed neutralizing LT-βR ligands, as a new therapeutic strategy based on 
data generated from their newly established mouse model for AIP. In their work, they have 
demonstrated that an overexpression of lymphotoxin (LT) α and β in the acinar cells  
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(Ela1-LTab mice) may lead to the development of an autoimmune condition strongly 
resembling the human AIP (Seleznik et al., 2012). 
1.2.1.5 Environmental Risk Factors 
Several important environmental risk factors such as allergy, radiation, viral or bacterial 
infections, alcohol and smoking, play an important role in the development of autoimmune 
diseases (Ai et al., 2003; Prummel et al., 2004). The interaction between smoking and some 
genes provide a high risk for development of autoimmune diseases (Bang et al., 2010; Plenge 
et al., 2007). Although smoking and alcohol consumption are known to be risk factors in CP, 
their contribution to the development of AIP is still unknown (Andriulli et al., 2010; Coté et 
al., 2011; DiMagno & DiMagno, 2003; Law et al., 2010; Yadav et al., 2009). 
The association between particular vaccination and autoimmune diseases has been 
reported in few rare cases. For example, in Guillain-Barré syndrome (GBS), it was suggested 
that sensitization by microbes may lead to autoimmune response to the targeted system of the 
host, which is based on the homology of amino acid between the gangliosides of the nerve 
system and the lipopolysaccharides (LPSs) of Campylobacter jejuni (Houliston et al., 2011; 
Yuki et al., 2004). A new hypothesis proposed that infectious agent can trigger an 
upregulation of the host immune response to self-antigens, which may cause autoimmune 
diseases (Yanagisawa et al., 2011). The regression of autoimmune thrombocytopenia after the 
eradication of Helicobacter pylori is supporting this theory (Jackson et al., 2005). However, 
the genetic contribution to autoimmune pancreatitis (AIP) remains elusive. 
1.2.1.6 Genetics of CP and AIP 
Recently the genetical basis of CP has been extensively studied. In this regard, 
Whitcomb et al. were the first who reported a mutation in the cationic trypsinogen gene 
(PRSS1), p.R122H, resulting in hereditary pancreatitis (Whitcomb et al., 1996). This gain-of-
function mutation stabilises activated trypsin by preventing its autolysis. Lately, more CP 
associated genes have been identified, and specifically genes that are known to be contributing 
factors rather than causative genes. Genes such as SPINK1 (Serine Protease Inhibitor Kazal 
type1) (Witt et al., 2000), CFTR (Cystic Fibrosis Transmembrane Regulator; the gene which 
is mutated in cystic fibrosis) and CTRC (Chymotrypsinogen C) are considered to be the best 
characterised susceptibility genes (Rosendahl et al., 2007; Sharer et al., 1998). Intriguingly, in 
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all above-mentioned genes, a loss of function has been reported following mutations in CP 
patients. In a study by Witt et al., a variation has been identified in the anionic trypsinogen 
gene PRSS2 that serves as a preventing factor against CP (Witt et al., 2006). 
The genetic basis of AIP has not been systematically investigated so far. As reported by 
Ota et al., two critical genes (i.e. HLA-DRB1 and ABCF1) in the HLA region were found to be 
related to the susceptibility to AIP (Ota et al., 2007). Interestingly, the human risk allele HLA-
DRB1*0405 predisposes class II transgenic Ab0 NOD mice to AIP (Freitag et al., 2010). 
Similar to patients with other autoimmune diseases, AIP patients have a particular HLA 
haplotype (i.e. DRB1*0405-DQB1*0401) (Guarneri et al., 2005; Klöppel et al., 2003) that 
serves as an important risk factor for AIP. Recently, two other risk factors have been reported 
for AIP: human Carbonic anhydrase II (CA-II) and α-Carbonic anhydrase of Helicobacter 
pylori (HpCA) that are significantly homologous and share segments that contain the binding 
motifs of the HLA molecule DRB1*0405 (Klöppel et al., 2003). Additionally, a mutation of 
DQ beta1 (substitution of aspartic acid at position 57) was identified as an important genetic 
factor for relapse of AIP (Park, Kim et al., 2008). Previous reports show that polymorphisms 
of the Cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene have been linked to the disease in 
Chinese and Japanese populations (Chang et al., 2007; Umemura et al., 2008). In 2013, an 
association between mutations in the protease serine 1 (PRSS1) gene and AIP has been 
reported for the first time (Gao et al., 2013). Furthermore, an association between mutations in 
the KRAS gene and pancreatobiliary carcinoma has been recently reported in patients with AIP 
(Ohtani et al., 2011). 
1.2.1.7 Mouse Models of AIP 
Pathological mechanisms and genetic factors regulating diseases can be studied using 
animal models of human diseases due to their genetical, anatomical and physiological 
similarities to humans. In addition, their unlimited supply, ease of manipulation, high 
reproductive rates and relative low cost of use make them valuable for the majority of genetic 
diseases studies. Over the last decade, our understanding of the cause and progression of 
human genetic diseases based on animal models studies have greatly improved. Furthermore, 
animal models have proven to be a powerful tool for the discovery of novel therapeutic targets 
(Simmons, 2008). Within animal models, mice are the predominantly used laboratory animals 
for studying the etiology and the pathogenesis of autoimmune diseases. For example, the 
alylaly (aly-/aly-) mouse is a unique model of spontaneous Sjögren's syndrome (Tsubata et al., 
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1996). As shown in Table 1.2, mice, rat or other species are useful tool for investigation of the 
pathoetiology of autoimmune diseases. 
Recent development of AIP animal models enhanced the understanding of the 
pathogenesis of the disease, which is a newly described form of chronic pancreatitis (Park et 
al., 2009). Several murine models have been employed to understand the cellular and genetic 
mechanisms involved in the development of AIP. For example, Davidson et al. reported that 
the administration of activated CD4+ T cells3 specific for the pancreatic enzyme amylase can 
induce pancreatitis in the experimental autoimmune pancreatitis models “DA(PR) rats” and 
“Lewis rats” (Davidson et al., 2005). Other models include the WBN/Kob rats that are used to 
study AIP with autoimmune extrapancreatic exocrinopathy and which show several features 
of the human condition, i.e. infiltration of CD8+ cells, deposition of tissue-specific IgG2b in 
the injured pancreas/lacrimal glands and decreased number of regulatory T cells (defined as 
CD4+ FoxP3+ cells)4 in the periphery of both sexes. Altogether, these results suggest that 
WBN/Kob rats represent a novel model for the study of AIP, Sjögren-like syndrome or multi-
focal fibrosclerosis in humans (Sakaguchi et al., 2008). Animal experimental models of 
autoimmune pancreatitis are listed in Table 1.2. 
The MRL strain is a well-known mouse model for AIP that was developed from several 
crosses of inbred strains. Theofilopoulos & Dixon `s showed that most of the MRL genome 
was derived from the LG/J strain with minor contributions from C3H/Di, C57BL/6, and 
AKR/J (Theofilopoulos & Dixon, 1984). The substrain MRL/lpr developed an SLE-like 
phenotype characterized by lymphadenopathy due to the accumulation of double negative 
(CD4-CD8-) and B220+ T-cells. These mice showed an accelerated mortality and both males 
and females were significantly affected. Furthermore, high concentrations of circulating 
immunoglobulins including elevated levels of autoantibodies such as Anti-nuclear antibody 
(ANA), Anti-single stranded DNA (anti-ssDNA), Anti-double stranded DNA (anti-dsDNA), 
Anti-Smith (anti-Sm) and Rheumatoid factors (RF) are detected in MRL/lpr substrain, which 
may lead to formation of immune complexes (Andrews et al., 1978; Perry et al., 2011). 
Previously, it has been shown that aged MRL/Mp-+/+(MRL/+) mice develop 
spontaneously an autoimmune pancreatitis. Several studies proposed that 
polyinosinic:polycytidylic acid (poly I:C), a synthetic analog of double-stranded RNA, 
                                                
3 CD stand for cluster of diffrentiation 
4 Forkhead-Box-Protein P3 
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triggers the development of autoimmune diseases including pancreatitis in a particular genetic 
background (Okada et al., 2005; Qu et al., 2002). Autoimmune pancreatitis, as a multi-
factorial disease, can be controlled by genetic and environmental factors. Therefore, MRL 
mice treated with polyinosinic:polycytidylic acid (poly I:C) might be a useful mouse model to 
study the pathogenesis of AIP (Qu et al., 2002). Using AlP-prone MRL/Mp mice, Fitzner et al 
showed that interferon gamma (IFN-γ), a T helper1 (Th1) pro-inflammatory cytokine, plays a 
key role in the inflammatory process. Therefore, they proposed that IFN-γ-enhanced AIP in 
MRL/Mp mice and can be useful to study the pathophysiology, diagnosis and therapeutic 
approaches for AIP (Fitzner et al., 2009). 
Recent studies showed that AIP-like diseases could be induced in most animal models 
by exposure to heat-killed E. Coli or adoptive transfer of autoreactive cells and self-antigens 
such as carbonic anhydrase II (CA-II) and lactoferrin (LF) (Haruta et al., 2010; Okazaki et al., 
2010). AIP-like pathological alterations were observed in pancreas and salivary glands of 
some mice models of AID (C57BL/6 and BALB/c) after repeated exposure to heat-killed  
E. Coli (Yanagisawa et al., 2011). AIP is induced when genetic factors such as haplotype of 
class II antigen of the major histocompatibility complex (MHC) are synchronized with the 
presence of commensal bacteria or pathogenic microorganisms (Haruta et al., 2012). 
The limited availability of animal model for research has slowed down the related 
studies on the pathophysiology and genetics of AIP. In the current study, a MRL/Mp mouse 
model (established by Kanno et al.) was chosen for three main reasons. First, it closely reflects 
the histopathological changes typical to human AIP. Second, the disease develops 
spontaneously (Kanno et al., 1992; Sorg et al., 2008) and may be further aggravated by trigger 
substances such as polyinosinic:polycytidylic acid (Qu et al., 2002) or IFN-γ (Fitzner et al., 
2009). Finally, its autoimmune pathogenesis, which was supported by induction of 
pancreatitis (in females) following adoptive transfer of splenic cells obtained from diseased 
mice (Kanno et al., 1992). It has been shown that MRL/Mp female mice exhibit early onset 
and higher severity of AIP as compared to males (Kanno et al., 1992; Sorg et al., 2008). The 
murine disease cannot be simply classified according to the human subtype system due to the 
lack of IgG4 in rodent species. However, some similarities exist between the AIP of MRL/Mp 
mice and human AIP subtype 1. For instance, the lack of  typical granulocytic epithelial 
lesions, and the absence of non-specific autoantibodies (Kanno et al., 1992; Sorg et al., 2008). 
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Table 1.2 Summary of animal experimental models of autoimmune pancreatitis 
Authors Year Animals Target 
antigens 
Induction Organs with 
lesions 
Effector 
cells 
Kanno et al. 1992 MRL/lpr mice ?* Spontaneous Pancreas T cells 
Nishimori et al. 1995 PL/J mice CA-II Subcutaneously 
immunised 
with CA-II 
Salivary ? 
Tsubata et al. 1996 aly−/aly−mice ? Spontaneous Pancreas, Peyer’s 
patch  
deficiency 
CD4+ T cells 
Haneji et al. 1996 nTx-NFS/sld 
mice 
a-fodrin Spontaneous Salivary CD4+ T cells 
Uchida et al. 1998 nTx-BALB/c 
mice, and  
nude mice 
CA-II Subcutaneously 
immunised 
with CA-II 
Pancreas, bile duct, 
salivary glands , 
 renal tubule 
CD4+ Th1 
cells 
Uchida et al. 
 
1998 nTx-BALB/c 
and nude mice 
LF Subcutaneously 
immunised 
with LF 
Pancreas, bile duct, 
salivary glands, renal 
tubule 
CD4+Th1 
cells 
Vallance et al. 1998 MHC-class II-
deficient mice 
? ? Pancreas, colon CD8+ T cells 
Ueno et al. 1998 BALB/c mice CA-II Intraperitoneally 
immunised 
with CA-II 
Bile duct CD4+ T cells 
Mustafa et al. 1998 MRL/lpr mice ? ? Salivary Th1 
Uchida et al. 2002 nTx-BALB/c 
mice and nude 
mice 
CA-II, LF Subcutaneously 
immunised 
with CA-II, LF 
Pancreas, bile duct, 
salivary gland, 
renal tubule 
CD4+ Th1 
cells 
QU et al. 2002 MRL/+, 
MRL/lpr 
? poly I:C salivary, bile duct,  
renal tubule 
CD4+ T cells 
Watanabe et al. 2003 
 
C57BL/6 mice ? LP-BM5 Pancreas, salivary 
gland, liver, kidney, 
lung 
CD4+ T cells 
Davidson et al. 2005 DA(PR) rats 
and Lewis rats 
amylase 
? 
Amylase-specific 
T cell 
Pancreas 
 
CD4+ T & 
CD8+ T cells 
Sakaguchi et al. 2008 WBN/Kob rats 
(Wistar Bonn 
Kobori rat) 
? Spontaneous Pancreas and 
lachrymal gland  
CD8+ T cells 
Meagher et al. 2008 
 
NOD.CD28K
O mice 
Amylase Spontaneous Pancreas  
 
CD4+ T cells 
Haruta et al. 2010 C57BL/6 mice ? E. coli Pancreas, salivary 
gland 
T cells 
 
CA-II, carbonic anhydrase II; CD; cluster of differentiation, LF, lactoferrin; nTx, neonatal 
thymectomy; LP-BM5 murine leukemia virus; Th1, T helper 1; poly I:C,	   polyinosinic:polycytidylic	  acid. 
*? = There is no information available and target remains to be explored. 
Adopted from (Okazaki et al., 2001; Okazaki et al., 2008; Park et al., 2009). 
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1.3 Strategies to Identify Susceptibility Genes of Complex Diseases  
Everybody has a different genome due to the gene variations, which contribute to most 
of the complex diseases. Therefore, any attempt to identify susceptibility genes for a particular 
disease improves our knowledge of the molecular mechanisms, diagnosis and prevention of 
the disease, as well as finding new targets for the development of therapeutic strategies. Many 
interacting genes and environmental factors affect complex diseases and each of these factors 
may play a role, which can have an effect on the disease in a certain genetic and 
environmental background (Lander & Schork, 1994). Because of this complexity, large source 
of families involving several affected individuals are required to reach significant result in 
human linkage analysis. Using inbred mice, which are genetically homogenous, could be an 
alternative for this purpose. Inbred mouse strains with various genome backgrounds will show 
variant susceptibility to a particular disease that resembles human disease. Crossing between 
the susceptible strain and the resistant strain could be helpful in identifying Quantitative Trait 
Loci (QTLs) affecting the susceptibility to the disease as well as genes underlying 
susceptibility to human disease. Human studies of prone gene can be carried out as soon as the 
susceptible gene is identified in mice. 
1.3.1 From Disease to Quantitative Trait Loci by Linkage Analysis 
To date, different strategies are developed to identify QTLs. Within these strategies, the 
location of genes that cause genetic diseases could be essentially identified by linkage 
mapping. Therefore, the first breeding step performed in a linkage analysis is an outcross 
between two inbred strains or between one inbred strain and a non-inbred animal that contains 
a genetic variant. The main types of crosses that are usually used in mouse genetics are 
N2 backcrosses and F2 intercrosses, which are obtained from F1 mice intercrossing. 
N2 backcross and F2 intercross are commonly used for the linkage analysis to identify QTLs 
in selected susceptible and resistant strain (Abiola O et al., 2003). To produce F2 intercross 
mice, two parental strains that have the same heterozygous genotype at designated loci are 
crossed to produce F1 mice. Then these F1 mice are intercrossed to produce next generation 
(F2). In contrast, N2 backcrosses are obtained from crossing between F1 mice (heterozygous 
for alleles obtained from two parental strains) and one of those parental strains. Therefore, 
F2 intercrosses have been chosen for linkage analysis (due to the dual recombination events in 
the same number of mice) rather than N2 backcrosses. Two examples in this filed are 
identification of QTLs controlling autoimmune diabetes in NOD mice and genetic linkage 
 Introduction  
16 
 
 
analysis of collagen-induced arthritis in F2 intercross mice (Jirholt et al., 1998; Wicker et al., 
1995). 
1.3.2 QTLs Mapping 
Quantitative trait loci (QTLs) are stretches of genome that contain or are linked to one 
or more susceptibility genes, which are controlling a quantitative trait. Mapping the QTLs is 
done using molecular tags such as Amplified fragment length polymorphism (AFLP) or more 
commonly, single nucleotide polymorphisms (SNPs). Quantitative traits refer to phenotypes 
that differ in degree and can be associated with polygenic effects, i.e., product of two or more 
genes, and their environment. However, it remains challenging to identify and map QTLs 
considering many genes that located inside this genomic region, possible epistasis or 
interactions between QTL and many additional sources of variation (Doerge, 2002). In an 
attempt to increase mapping resolutions (fine mapping of QTL), narrowing the confidential 
interval (CI) is required. The main goal of fine mapping of QTL is to identify candidate genes 
within a certain region (<1~5 cM or ~ 1-2 Mbp) of the genome. Several approaches were 
proposed for fine-mapping of QTLs, i.e. Advanced intercross line (AIL), subcongenic strains, 
partial advanced intercross lines (PAIL), haplotype analysis, Yin-Yang crosses, outbreed 
stocks, and recombination inbred lines (RIL) (Flint, 2011; Flint et al., 2005). 
An Advanced Intercross Line (AIL) is originated from two parental inbred strains by 
intercrossing and followed by subsequently and randomly intercrossing, avoiding brother-
sister mating, for several generation. This approach provided animals, which accumulated 
many recombination events (Yu et al., 2007), which can be useful for QTLs identification. 
The first step begins with crossing of two parental strains to produce F1 mice. The procedure 
continues by intercrossing these F1 mice to produce F2. To produce following generations, 
randomly intercrossing within each generation is performed via at least 50 random mating per 
generation. Sufficient random mating in each generation provide the heterogeneity of all the 
alleles in the genome, which makes AIL valuable for fine mapping of all the QTLs identified 
in the mice. However, the obvious limitations of such approach are time and space that are 
required to produce the experimental animals. 
Subcongenic Strain is another commonly used fine-mapping approach. These strains 
are produced from congenic strains containing the QTLs genome intervals. A set of 
subcongenic strains have a short differential segment and recombination events in different 
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locations of the genome. Consequently, QTLs can be distinguished by evaluation of a set of 
these strains. The refining size of a QTL is dependent on overlapping and the number of 
subcongenic strains (Fehr et al., 2002). Additionally, as subcongenic strains are genetically 
identical mice, they can be used to detect and refine the QTLs that have only small effects. 
However, besides being time consuming, other inadequacies of this approach are again the 
large space and workload needed. 
Partial Advanced Intercross Lines (PAIL) have been developed by combining the 
advantages of both AIL and subcongenic strains. PAIL mice are generated using a series of 
intercrosses between congenic mice and the wild-type mice as parental strains (Johannesson et 
al., 2005). With identical genetic background and high recombination events, PAIL mice can 
be used to refine a small effect QTL into a rather small genome region. However, PAIL also 
has the shortcomings of AIL and subcongenic strains, i.e. being time and space consuming. 
Haplotype analysis might be the fastest method for QTLs fine-mapping, which reduced 
the required time designed for genetic analysis for complex diseases from months to seconds 
(Grupe et al., 2001). The method is based on identification of a QTL in different inbred-strain 
crosses following by combination of the strain distribution pattern with mapping data, to 
refine the region that contains the functional variant (Flint et al., 2005). 
Yin-Yang crosses, outbred stocks, and recombination inbred lines (RIL) are some other 
approaches recommended for QTLs fine-mapping (Flint et al., 2005). It is also important to 
keep in mind that each approach has own advantages and disadvantages. Therefore, the choice 
of method for fine mapping of QTLs is dependent on particular phenotypes or QTLs rather 
than method itself. 
1.3.3 Identification of Susceptibility QTL of AIP in Four-way AIL  
Because of accumulated numerous combination events, AIL is a powerful approach for 
high-resolution fine mapping of QTLs compared with conventional F2 intercross N2 
backcross, (Yu et al., 2006). Therefore, a four-ways advanced intercross line (4-way AIL) 
could provide much more detailed approach to identify and refine the regions (QTLs) that are 
contributing to certain diseases. 
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1.4 Aims of This Study 
The main three aims that underlie this thesis are: 
• Identification of genes contributing to autoimmune diseases susceptibility, 
• Identification of novel QTLs that control the susceptibility to AIP, 
• Investigation of immunopathogenesis of AIP in the four-way AIL animal 
model of AIP. 
To address the first aim of the thesis and to identify susceptible genes to autoimmunity 
we had generated an outbred intercross mouse line, a four-way autoimmune-prone advanced 
intercross line (AIL), originating from MRL/MpJ (spontaneous autoimmune pancreatitis), 
BXD2/TyJ (spontaneous arthritis), NZM2410/J (spontaneous Lupus) and Cast/EiJ mice (wild 
derived strain). The progeny of this cross represents a large family with higher incidence of 
common autoimmune diseases such as arthritis, lupus and AIP. Next, a classical quantitative 
trait mapping approach was performed to identify novel loci controlling susceptibility to AIP. 
Finally to study the immunopathogenesis of AIP, the role of regulatory T cells (Tregs) and  
T helper cells was addressed using the four-way AIL mouse model. 
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2  Materials and Methods 
2.1 Materials 
2.1.1 Instrument & Laboratory supplies 
Centrifuge Eppendorf, Germany 
Centrifuge (Rontina 464) Hettich, USA 
LABOFUGE centrifuge 400R Thermo Scientific 
Microcentrifuge, mikro 200R Beckman Coulter, Germany 
BD FACS calibor Becton Dickinson (BD), USA 
Precision pipette set (10/20/100/200/1000 µl) Eppendorf, Germany 
Sterile Hood (laminarair @ HB2448) Heraeus Instrument, Germany 
Light microscope Zeiss, Oberkochen, Germany 
Light microscope Leica, Germany 
Zeiss axiophot microscope Axiophot, Zeiss, Oberkochen, Germany  
Microtome Leica CM1850, Germany 
Microtiter plates (96well, round bottom ) Nunc, Germany 
Cryo pure tube Sarstedt, Germany 
Cell strainer 70 Becton Dickinson(BD), USA 
Precision pipet set (10, 20, 100, 200 &1000 µl)  Eppendorf, Germany 
Round-­‐bottom FACS tubes (5 ml) Becton Dickinson, USA 
2.1.2 Commercial kits 
QIAamp® DNA Blood Mini Kit  QIAGEN, Hilden, Germany 
QIAamp® DNA Mini Kit QIAGEN, Germany 
ABC staining kit  Vector Laboratories, Burlingame, 
California, USA 
DNeasy Blood & Tissue Kit QIAGEN, Germany 
RNeasy Mini Kit QIAGEN, Germany 
RNAlater Ambion, Germany 
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2.1.3 Chemical and Reagents 
NaCl Roth, Germany 
KCl Merck, Germany 
Na2HPO4.2H2O Merck ,Germany 
KH2PO4 Merck, Germany 
Tris-HCl Roth, Germany 
EDTA5 Roth, Germany 
PBS6 (10X) Gibco, Life Technologies, USA 
FCS7 PAA, GE Healthcare, Germany 
RPMI 1640 medium PAA Laboratories, Germany 
NaOH Merck, Germany 
Trypanblue Biochrom, Germany 
Penicillin/Streptomycin PAA Laboratories, Germany 
D-MEM Medium GIBCO®, USA 
Fetal calf serum (FCS) GIBCO®, USA 
Penicillin/Streptomycin GIBCO®, USA 
RPMI 1640 Medium GIBCO® ,USA 
Trypsin-EDTA (1x) GIBCO®, USA 
Tissue-Tek® O.C.T™ Compound Sakura Finetek Europe B.V, The 
Netherlands 
Erythrocyte lysis buffer was obtained from  QIAGEN®, Germany 
1X Red Blood Cell Lysis Buffer eBioscience, USA 
PBS Gibco, USA 
Formafix 4%  Grimm med. Logistik GmbH; Germany 
Paraffin Roth, Germany 
Paraformaldehyd Morphisto, Germany 
2.1.4 Antibodies 
FITC anti-mouse CD4 BD PharMingenTM, USA 
PE anti-mouse B220 BD PharMingenTM, USA 
                                                
5 Ethylenediaminetetraacetic acid 
6 Phosphate buffered saline 
7 Fetal calf serum 
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PerCP-Cy5.5 anti-mouse CD8 BD PharMingenTM, USA 
APC anti-mouse CD3 BD PharMingenTM, USA 
FITC anti-mouse CD44 BD PharMingenTM, USA 
PE anti-mouse CD62L BD PharMingenTM, USA 
PerCP-Cy5.5 anti-mouse CD4 BD PharMingenTM, USA 
APC anti-mouse CD69 BD PharMingenTM, USA 
FITC anti-mouse CD86 BD PharMingenTM, USA 
PE anti-mouse MHC Class II eBioscience, USA 
PerCP-Cy5.5 anti-mouse CD19 BD PharMingenTM, USA 
PE anti-mouse PDCA-1 eBioscience, USA 
APC anti-mouse CD11c BD PharMingenTM, USA  
PE anti-mouse IL17* BD PharMingenTM, USA 
APC anti-mouse CD8 BD PharMingenTM, USA 
PE anti-mouse FoxP3 eBioscience, USA 
FITC anti-mouse IFN gamma* BD PharMingenTM, USA 
APC anti-mouse IL4* BD PharMingenTM, USA 
FITC anti-mouse CD25 BD PharMingenTM, USA 
PE Armenian Hamster IgG Isotype Control eBioscience, USA 
Anti-CD4 Immunotools, Friesoythe, Germany 
Anti-CD45R (B220) Immunotools, Friesoythe, Germany 
Anti-CD8 Santa Cruz Biotechnologies Inc., USA 
Anti-F4/80  eBioscience, San Diego, USA 
*These antibodies target the intracellular (IC) antigens. PE; Phycoerythrin, APC; Alkaline 
Phosphate Conjugated, FITC; Fluorescein Isothiocyanate conjugated, (PerCP)-Cy5.5; 
Peridinin chlorophyll protein -Cy5.5. 
2.1.5 Buffers and Solutions 
10 x PBS Buffer: 
 NaCl 1.37 M 80 g 
 KCl 27 mM 2.0 g 
 Na2HPO4. 2H2O 80 mM 14.4 g 
 KH2PO4 17.6 mM 2.4 g 
 Dissolve in 800 ml dH2O, adjust the pH to 7.4, and add dH2O until a 
total volume of 1 liter and autoclave. 
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FACS washing buffer  
 1 x PBS, 0.04% NaN3, 5% FCS 
 
FACS-Wash Buffer (Staining Buffer): 
 1 X PBS 
 3% heat-inactivated FCS 
 FCS buffer adjust pH to 7.4-7.6 
 Filter (0.2 µm pore membrane), and store at 4 ºC 
 
Fc Block: 
 Dilute anti-CD16/CD32 (0.5 mg/ml) 
 Add 120 µl Fc-block + 1080 µl of FWB dilution factor 1/10 
 
TE Buffer 
 Tris-HCl 10 mM, EDTA1 mM, 
 Adjust the pH to 8.0 
 
2.1.6 Mice 
All mice used in this study were housed under climate-controlled environment with 
12-h light/darkness cycle with food and water ad libitum in the animal facility at the 
University of Rostock. The procedures, assays and all animal studies were pre-approved by 
local governmental authority, i.e. the Animal Care Committee of Mecklenburg-Vorpommern. 
The parental strains MRL/MpJ, NZM2410/J, BXD2/TyJ and Cast/EiJ were purchased from 
Charles River Laboratories (Sulzfeld, Germany). 
2.1.6.1 Generation of Four-way Autoimmune Advanced Intercross Line (AIL) 
In this study, an outbred four-way autoimmune prone advanced intercross line (AIL) 
was originated from the parental mouse strains MRL/MpJ and NZM2410/J, BXD2/TyJ and 
Cast/EiJ (Figure 2.1). Parental MRL/MpJ mice are prone to develop spontaneous AIP as 
previously described, in an age and gender-specific manner, whereas the other strains 
displayed no significant histopathological changes of the pancreas. The lupus-prone 
NZM2410/J strain was originated from NZB × NZW mice. The BXD2/TyJ mice are 
particularly well known for developing spontaneous arthritis and generalized autoimmune 
disease. In contrast, wild type strain Cast/EiJ is resistant to these diseases. The four parental 
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strains were intercrossed at an equal strain and sex distribution in order to maintain an equal 
distribution of the original strains in the following generations. The parental origin of 
generation 1 (G1) offspring mice was considered when setting up mating for the generation of 
G2 mice. This procedure was also followed for intercrossing G2 mice. At each time, at least 
50 breeding pairs were used as parents for the next generation of mice. In this work a 
quantitative trait mapping (QTL mapping) analysis was performed to identify quantitative trait 
loci associated with AIP in G4 mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic representation for mapping disease-QTLs: the autoimmunity four-way 
advanced intercross line (courtesy of Prof. Saleh Ibrahim) 
2.1.6.2 The Fourth Generation (G4) of Four-way AIL Mice 
A total of 351 mice from fourth generation (G4) of the four-way autoimmune-prone 
AIL were maintained in animal facility under specific pathogen-free conditions and monitored 
for clinical status and development of autoimmune diseases. In a joint work within our group, 
mice were assessed twice per week for onset, joint inflammation, skin disorders and any 
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abnormality. Six-month-old mice were sacrificed and samples were obtained for further 
analysis. The development of spontaneous AIP was assessed in parental strains and in the 
fourth generation (G4) of four-way advanced intercross line by scoring the severity of 
pancreatic lesions as described in section (2.2.1.2.1). Mice were kept under specific pathogen 
free conditions as mentioned above. 
2.2 Methods 
2.2.1 Protocol for AIP and Autoimmune Diseases Studies 
2.2.1.1 Sacrificing and Sampling 
For this study, six-months-old G4 mice of four-way advanced intercross line were 
subjected to the experiments according to the following protocols: 
• The mice were anaesthetized using diethyl ether and sacrificed by cervical 
dislocation. Weights of the mice were measured at autopsy. 
• Blood was collected and sera were obtained after centrifugation at 14000 rpm 
for 10 min, aliquoted (100    µμ𝑙 in each tube) and stored at -20 °C then at -80 ºC 
for further purposes (to assay autoantibodies using proteome arrays or ELISA, 
as well as to assay BUN, lipase, glucose and so on). 
• 1 cm-piece of mouse-tail tip was cut and placed in a 1.5 ml micro-tube on ice, 
then stored at -20 ºC for DNA isolation. 
• Abdomen was opened; pancreas, spleen, kidney, lymph nodes, liver and lung 
were taken for histopathological examination and other purposes. 
Pancreas 
Dissected pancreas was divided into 3 parts: 
• Left part (next to duodenum) was fixed in 4% phosphate buffered formalin for 
3 days. The tissues were then embedded in paraffin. Serial sections (5 µm) 
were used for histopathologic evaluation of pancreatic lesions after staining 
with haematoxylin and eosin (H&E). 
• The middle part has been quickly frozen in liquid nitrogen and stored at -80 ºC. 
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• The right part was placed in OCT, and then it has been frozen in liquid nitrogen 
and stored at -80 ºC until use. The 6 µm serial sections of this part of pancreas 
were stained for immunohistochemical studies. 
Spleen 
Weight of each dissected spleen was measured before it was divided it into 3 pieces: 
Ø One piece in RPMI (with 10% FCS) for following steps: 
• to prepare splenocytes suspension, 
• to count and to adjust the cell density to 106 cells in 10 µl of cell suspension,  
• To examine cell population/ subsets and activation, multicolour flow 
cytometric analyses were performed with antibody cocktails, i.e. B220, CD3, 
CD4, CD8, CD62 L, CD86, CD69, CD11c immediately after removing the 
spleen. 
Ø The second piece was placed in liquid nitrogen and stored at -80 ºC until use (for 
signaling proteome arrays, were shipped on dry ice for processing and analysis). 
Ø Finally, the last piece was placed in OCT, and has been frozen in liquid nitrogen 
and stored at -80 ºC (for subsequent pathology scores and antigen specific 
immunohistochemistry). 
Kidney 
Ø Left kidney was placed in formalin overnight and later embedded in paraffin. 
Ø In addition, the right kidney was divided into two parts; one part was placed in 
OCT and then frozen at -80 ºC. The other part of kidney was placed in liquid 
nitrogen and then stored at -80 ºC (for signalling proteome arrays). 
Lymph nodes 
Two lymph nodes (cervical or inguinal) were dissected and then placed into RNA later. 
The samples were incubated at 2-8 °C overnight, and were then archived at -20 °C for future 
studies. 
Lung & liver 
Dissected pieces of lung and liver were placed into OCT and has been frozen in liquid 
nitrogen and then stored at -80 ºC. 
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2.2.1.2 Spontaneous AIP 
Development of spontaneous AIP in parental strains (54mice) and fourth generation of 
intercross mice (G4) (163 males and 188 females) was assessed in 6-month-old mice by 
scoring the severity of pancreatic lesions as outlined below. 
2.2.1.2.1 Histology  
Half of the pancreas of each mouse was fixed in 4% phosphate buffered formalin and 
then embedded in paraffin. From paraffin-embedded pancreatic blocks, 5 µm thick sections 
were prepared and stained with Haematoxylin and Eosin (H&E), applying standard protocols. 
The histopathological evaluation of pancreatic lesions was performed employing a light 
microscope. Pathological changes in each sample were scored on a semi-quantitative scale 
from 0 (healthy pancreas) to 4 (severe AIP) grade, using an established scoring system with 
minor modifications (Qu et al., 2002; Sorg et al., 2008). Briefly, severity of pancreatic lesions 
was quantified as following: 
• Stage zero (0), no pathological changes; pancreas without mononuclear cell 
infiltration, indicating almost normal tissue morphology and organ integrity; 
• Stage one (1), minimal infiltration of periductal tissue with mononuclear cells 
but no parenchymal destruction; mononuclear cell aggregation and/ or 
infiltration within the interstitium without any parenchymal destruction; 
• Stage two (2), moderate periductal infiltration with mononuclear cells 
associated with beginning parenchymal destruction; focal parenchymal 
destruction with mononuclear cell infiltration; 
• Stage three (3), severe periductal inflammation and/ or more extended 
parenchymal destruction; diffuse parenchymal destruction but retained some 
intact parenchymal residue; 
• Stage four (4), diffuse mononuclear cell infiltration in pancreatic tissue except 
of pancreatic islets, destruction of acini and (partial) replacement by adipose 
tissue. 
All samples were blinded before evaluation. To estimate the incidence of pancreatitis in 
G4 mice, pancreatic lesions that scored ≥ 2 were defined as positive for AIP. The slides were 
reviewed and scored by Prof. Horst Nizze as a qualified pathologist and Prof. Robert Jaster. 
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2.2.1.2.2 Immunohistochemistry 
The other half of the pancreas was embedded in OCT compound (Sakura Finetek 
Europe B.V, The Netherlands) and then frozen in liquid nitrogen and stored at -80 °C. An 
immunohistochemical (IHC) staining was performed using antibodies specific for CD4, CD8, 
CD45R (B220) and CD138. Six mm thick serially cut sections were fixed by incubation in 
ice-cold methanol for 1 min at 4 °C. Subsequently, sections were washed three times with 
phosphate buffered saline (PBS), and stained using the VECTASTAIN ABC staining kit 
(Vector Laboratories, Burlingame, California, USA) according to the manufacturer’s 
instructions (Figure 2.2). The following mouse specific primary rat antibodies were used for 
the characterization of leukocyte subsets: anti-CD4 (Immunotools, Friesoythe, Germany), 
anti-CD8 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), anti-CD45R (B220) 
(Immunotools, Friesoythe, Germany), and anti-CD138 (eBioscience, San Diego, California, 
USA). All primary antibodies were yielded in rats, directed against the relevant murine 
antigen and used at a 1:100 dilution. The sections were counterstained with Haematoxylin and 
examined by light microscopy (Axioskop 40, Zeiss, Oberkochen, Germany). 
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Figure 2.2 Schematic representation of immunohistochemical staining protocol performed on 
frozen sections.  
Based on VECTASTAIN ABC staining kit protocol (Vector Laboratories, Burlingame, California, 
USA). (http://www.vectorlabs.com/data/protocols/PK-4000.pdf)  
 
Air dried  section  
Fix sections with the appropriate fixative 
Transfer slides into buffer 
Blocking solution for 10 min 
Normal sera in PBS for 5 min 
Washing in buffer for 5 min 
Incubation for 20 min with diluted normal serum containting secondary antibody 
Blot excess serum from sections 
Incubation for 30 min with primary diluted antiserum 
Washing slides for 5 min 
Incubation for 30 min with diluted biotinylated secondary antibody solution 
Washing slides for 5 min 
Incubation for 30 min with VECTASTAIN® ABC Reagent 
Washing slides for 5 min 
Incubation in peroxidase substrate solution (until desired stain  intensity develops) 
Rinse sections in tap water 
Counterstain, clear and mount 
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2.2.2 Molecular Biological Methods 
2.2.2.1 Isolation of Mouse Total DNA 
Genomic DNA was isolated according to the following protocol: mouse-tail tips (0.5-
0.8 cm) were incubated with 500 µl 50 mM NaOH for 2 hours at 95 °C. In order to make 
uniform solution, the samples were mixed by occasional vortexing during incubation period. 
DNA neutralization was done by adding 50 µl of 1 M Tris-HCl (pH 8.0) in each tube. 
Afterwards, 500 µl double-distilled water (dd H2O) was added to the tube and followed by 
centrifugation at 10,000 g for 5 min. Finally, the supernatant was discarded and the pellets 
were dissolved as total mouse DNA. The DNA samples were then stored at -20 oC. 
For genotyping using Illumina murine High Density array (Illumina, California, USA), 
pure genomic DNA was isolated with the DNeasy Blood & Tissue Kit according to 
manufacturer's instructions. Briefly, a 0.5 cm mouse-tail tip was incubated with 180 µl buffer 
ATL and 20 µl Proteinase K at 56 °C until the tissue was completely lysed. Then 20 µl 
RNase-A was added to eliminate the RNA from sample. In the next step, the sample was 
incubated with 200 µl buffer AL for 10 min at 70 °C, then 200 µl ethanol were added and the 
sample was applied to the QIAamp spin column. Finally, the DNA was eluted by using AE 
buffer after washing with AW1 and AW2 buffers. 
2.2.2.2 Quantitative Trait Loci (QTLs) Identification 
To identify quantitative trait loci (QTLs) associated with autoimmune diseases, we 
established an advanced intercross line originating from MRL/MpJ parental mice and the 
following three mouse strains: Cast (healthy controls), BXD2 (susceptible to collagen-induced 
arthritis) and NZM (a model of Lupus erythematosus). This concept was chosen to identify 
both general autoimmune disease-associated loci and AIP-specific QTL. Therefore, the fourth 
generation (G4) of outbred intercross mice was characterized phenotypically by scoring 
histopathological changes of the pancreas and genotyped with SNP arrays (Illumina, USA). 
2.2.2.3 QTL Mapping 
A total of 330 mice of the fourth generation were genotyped by a set of 1400 single 
nucleotide polymorphisms (SNPs) using an Illumina murine HD array (Illumina, California, 
USA). Genotype/ phenotype correlation was performed with the R version of HAPPY (Mott 
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et al., 2000) in version 2.3 beta on Debian Linux in collaboration with Dr. Steffen Möller 
(Möller et al., 2010). The data from all chromosomes were analysed together with an additive 
model and their log P value and tested positively against 1000 permutations for pointwise 
significance (P <0.001). The flanking regions of QTLs were determined manually by a drop of 
1.5 to both sides to the peak. 
2.2.3 Immunological Methods  
2.2.3.1 Flow Cytometry 
2.2.3.1.1  Cell Surface Markers Staining 
Single cell suspensions preparation: In this study, to analyse subtypes of T cells, B 
cells and dendritic cells, single-cell suspensions from spleen of G4 mice were prepared as 
following: One third of mouse spleen was excised, suspended in 5 ml RPMI-1640, dissociated 
by using a 70 µm nylon cell strainer and washed twice in PBS. The cells were pelleted by 
centrifugation at 1200 rpm for 5 min at 4 °C. The supernatant was discarded and the pellet 
resuspended in 3 ml of 1 X RBC (red blood cell) lysis buffer. Then, the tubes were incubated 
on ice for 4-5 minutes with occasional shaking. The reaction was stopped by diluting the lysis 
buffer with 5 ml of RPMI. The cells were centrifuged (at 1200 rpm for 5 min), then washed 
with 10 ml medium to remove lysis buffer (2 X wash). The cells were spin at 1200 rpm for 5 
min at 4 °C and then resuspended cells in 1 ml medium. Cell numbers were counted and 
viability analyses were done (10 µl cell + 50 µl Trepan Blue + 40 µl FWB, dilution factor 
1/10). Volumes were corrected to 100 million cells/ml. Then, 10 µl of adjusted cell 
suspensions (equal to 106 cells) were added to each well for surface marker staining. For 
intracellular staining, 12 µl of cell suspensions were added to each well. In addition, a second 
round of lyses was performed for some samples with a small number of residual red cells. 
Block Fc Receptors step: Cells were pre-incubated with 2 µl anti-CD16/CD32 (dilution 
factor 1/10) per million cells for 5-10 min on ice prior to staining. 
Antibody preparation and incubation: The cocktails of antibodies were prepared and 
diluted to previously determined optimal concentration of primary antibody in staining buffer 
(Table 2.1). 2 µl of antibody-cocktails were dispensed to each well in 96-well plate. Two µl of 
staining buffer was added to each unstained or negative control wells and mixed gently.  
The 20 min incubation in dark on ice was performed for all samples. Dependent on our 
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preliminary experiments, for some antibodies incubation times were longer. Following the 
incubation period, two washing steps were performed by adding 200 µl of FACS wash buffer 
(FWB). Cells were centrifuged at 2000 rpm for 2 min at 4 °C and the supernatant was 
discarded. The stained cells were fixed with 1% paraformaldehyde for 10-20 min at 4 °C 
followed by centrifuging. The supernatant was discarded. The stained cell pellets were 
resuspended in FWB, transferred to FACS-tubes and subjected for analysis by flowcytometer. 
2.2.3.1.2 Fixation and Permeabilization of Cells for Intracellular Cytokines  
Fixation: Resuspended cells from previous steps were fixed in 4% paraformaldehyde 
for 10-20 min at 4 °C. The supernatant was removed and the cells were resuspended in FWB 
and then kept in the plate at 4 °C. Fixed cells were washed two times with FWB before next 
steps. 
Permeabilizing: Fixed cells were resuspended in 0.3% Saponin (vortex and mix) in 
FWB for 10 min. The cells were centrifuged and the supernatant was discarded. 
Staining for Intracellular Cytokines: The fixed/permeabilized cells were resuspended 
in 0.3% Saponin before intracellular staining for Foxp3, IFN-γ, IL4 and IL17. The 
resuspended cells were incubated with 2 µl of cocktails containing a pre-determined optimal 
concentration of a fluorochrome-conjugated anti-cytokine antibodies or appropriate negative 
control at 4 °C for 30 min in the dark. The cells were washed two times with  
0.1% Saponin in FWB, then spun down at 2000 rpm for 2 min. The supernatant was discarded 
and cells were resuspended in FACS buffer. Cells suspensions were transferred to the tubes 
for acquisition on flowcytometer. For performing multiple colors staining, fluorochrome-
labeled antibodies were added simultaneously to cell suspension in each well followed by 
incubation and washing steps as described above. All steps were performed in the cold and the 
samples protected from light during working with fluorescent antibodies. For all cytokines, 
data acquisitions were performed for cells at the same day for subsequent analysis. To assess 
cell numbers, all cells were acquired and analyzed with BD CellQuest pro software (BD). As 
shown in Table 2.1, cocktails of antibodies were prepared in a final volume of 200 µl. 
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Table 2.1 Flow cytometry antibodies` panel 
Basic T cells  
Add 160 µl FWB*               + 10 µl of anti-CD3 (APC) (0.2 mg/ml) 
10 µl of anti-CD4 (FITC) (0.5 mg/ml) 
10 µl of anti-CD8 (PerCP-Cy5.5) (0.2 mg/ml) 
10 µl of anti-B220 (PE) (0.2 mg/ml) 
CD4 Memory/ Activated  
Add 160 µl FWB             + 10 µl of anti-CD4 (PerCP-Cy5.5) (0.2 mg/ml) 
8 µl of anti-CD44 (FITC) (0.5 mg/ml) 
10 µl of anti-CD62L (PE) (0.2 mg/ml) 
12 µl of anti-CD69 (APC) (0.2 mg/ml) 
CD8 Memory/ Activated  
Add 160 µl FWB             + 10 µl of anti-CD8 (PerCP-Cy5.5) (0.2 mg/ml) 
8 µl of anti-CD44 (FITC) (0.5 mg/ml) 
10 µl of anti-CD62L (PE) (0.2 mg/ml) 
12 µl of anti-CD69 (APC) (0.2 mg/ml) 
B cell Activation  
Add 160 µl FWB             + 10 µl of anti-CD19 (PerCP-Cy5.5) (0.2 mg/ml) 
10 µl of anti-CD69 (APC) (0.2 mg/ml) 
8 µl of anti-CD86 (FITC) (0.2 mg/ml) 
14 µl of anti-MHC Class II (PE) (0.1 mg/ml) 
Dendritic cells  
Add 170 µl FWB             + 10 µl of anti-CD11c (APC) (0.2 mg/ml) 
10 µl of anti-PDCA-1 (PE) (0.2 mg/ml) 
10 µl of anti-CD86 (FITC) (0.5 mg/ml) 
Regulatory T cells  
Add 190 µl FWB            + 6/1 a: 10 µl anti-CD4 (PerCP-Cy5.5) (0.2 mg/ml) 
6/2 a: 10 µl anti-CD8 (APC) (0.2 mg/ml) 
6/2 b:10 µl anti-FoxP3** (PE) (0.2 mg/ml) 
T helper 1/ Th2/ Th17   
Add 190 µl FWB            + 
 
7a: 10 µl anti-CD4 (PerCP-Cy5.5) (0.2 mg/ml) 
7b/1: 10 µl anti-IL17** (PE) (0.2 mg/ml) 
7b/2: 10 µl anti-IFN-γ ** (FITC) (0.5 mg/ml) 
7b/3: 10 µl anti-IL4** (APC) (0.2 mg/ml) 
 
*FWB, FACS wash buffer  
**These antibodies target antigens that are intracellular (IC), and thus require special treatment. 
DCs, Dendritic cells; Tregs, Regulatory T cells; Th1/Th2/ Th17, T helper 1, 2 and 17cells; IL, 
interleukin. 
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2.2.3.2 Cells Subpopulation Determination 
2.2.3.2.1 B cell and T cell Subsets 
To examine cell population and subsets, the spleen cell suspensions were stained for 
basic T cell markers (CD3, CD4, CD8, B220 antibodies) and for B cell activation markers 
(CD19, CD69, CD86, MHC Class II antibodies) as shown in Table 2.1. 
To determine the ratio of CD4+ to CD8+ T cells, single cell suspensions from spleens of 
G4 mice (1x106 cells) were incubated with Fc-block at room temperature and then stained for 
15 min with CD4 (FITC-anti-mouse) and CD8 (PerCP-Cy5.5-anti-mouse antibodies). After 
two times washing with FACS buffer, cell subpopulations were determined. The percentage of 
CD4+ cells was divided by the percentage of CD8+ cells to calculate the CD4/CD8 ratio. 
2.2.3.2.2 Dendritic cells Subsets  
Dendritic cells (DCs) are specialized antigen-presenting cell (APCs), which control T-
cell responses as well as the differentiation of T helper subtypes (Bailey et al., 2007; 
MacDonald et al., 2002; Pulendran et al., 1999). In addition, it has been reported that DCs can 
differentiate into Foxp3+ Tregs in the presence of transforming growth factor-β (TGF-β), 
which could suppress autoimmune rejection of pancreatic islets in diabetic NOD mice (Luo et 
al., 2007). Therefore, the anti-CD11c, anti-plasmacytoid dendritic cell antigen 1 (PDCA-1) 
and anti-CD86, were used to identify DCs in G4 mice by flow cytometry. 
2.2.3.2.3 Regulatory Tcells Subpopulation 
Regulatory T cells (Tregs), primarily known as suppressor T cells, are a subpopulation 
of T cells which modulate the immune system, maintain tolerance to self-antigens and shift B 
cell to IgG4-producing plasmacytes. Tregs are involved in the development of various 
autoimmune diseases as well. Mouse models have proposed that modulation of Tregs can treat 
autoimmune disease. Regulatory T cells actively suppress activation of the immune system 
and prevent pathological self-reactivity, i.e. autoimmune disease. The severe autoimmune 
syndrome that results from a genetic deficiency in regulatory T cells evidences the critical role 
of Treg cells within the immune responses (Lu & Rudensky, 2009; Sakaguchi et al., 2009; 
Wildin et al., 2002; Wing & Sakaguchi, 2013). Recent research has shown that regulatory  
T-cells are determined by expression of the forkhead family transcription factor, (FOXP3, 
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forkhead box P3), which can be used as a good marker for mouse CD4+CD25+ T cells 
(Koyabu et al., 2013). Thus, to investigate the role of the Tregs in the pathophysiology of AIP, 
we analyzed the Tregs in the spleen of G4 mice using anti-CD4, anti-CD8 and anti-FoxP3 
markers (Table 2.1). 
2.2.3.2.4 T helper Subtyps 
T helper subtypes have been implicated in the regulation of many immune responses 
(Romagnani, 1992). Several distinct cytokine secretion patterns have been defined among 
murine CD4+ T cells. The different cytokine patterns lead to different functions of the types of 
T cell. T helper 1 (Th1) cells produce interleukin 2 (IL2), tumour necrosis factor-beta and 
gamma-interferon (IFN-γ), which is their effector cytokine. T helper 2 (Th2) cells are 
excellent helpers for B-cell antibody secretion, particularly IgE responses. Th2 cells are 
triggered by IL4 and express IL4, IL5, IL6 and IL10. Their effector cytokines are IL4 and IL5. 
T helper17 (Th17) cells are considered as a new subset of cells critical to the development of 
rheumatoid arthritis (RA). IL17 plays an important role in the pathogenesis of RA and the 
level of Th17 cells is associated with disease activity in RA (Kim et al., 2013). 
Several researches suggested that the imbalance in T helper-subset activities might play 
a role in the pathogenesis of autoimmune diseases (Sudzius et al., 2013; Ulivieri & Baldari, 
2013). Therefore, in this study intracellular cytokines (IFN-γ, IL4 and IL17) and T helper 
subsets of spleen lymphocytes were examined using flow cytometry in this study. 
2.2.4 Statistical Analysis 
All acquired data, measurements and information were exported to an Excel file. 
Genotype/phenotype correlation was analyzed for statistical significant with the R version of 
Happy in version 2.3 beta on Debian Linux. The data from all chromosomes were analysed 
together by an additive model. The significance of P values was confirmed for every SNP by 
comparison to 1000 permutations (P<0.001). The flanking regions of QTLs were determined 
manually by a drop of 1.5 to both sides to the peak. Scientific data and schemes were created 
and visualized using Power Point. 
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3 Results 
3.1 Phenotyping Analysis of 4-way Autoimmune-prone Intercross Mouse Line 
In this work, a genetically diverse mouse line was generated by intercrossing AIP-
susceptible MRL/MpJ mice (Kanno et al., 1992; Sorg et al., 2008) and three resistant mice 
strains BXD2, NZM and Cast and their offsprings for several generations. The genetic 
diversity of four-way autoimmune-prone intercross mouse line is identified by the different 
morphological traits, such as weight, tail length or coat colour. 
Phenotypic characterisation of spontaneous AIP in parental strain and in G4 mice was 
carried out at age of 6 month by scoring the severity of AIP-typical pancreatic lesions in H&E 
paraffin sections of pancreatic tissue specimens. Out of 351 G4 mice analysed, 12.8% of all 
animals (45 mice) displayed signs of parenchymal destructions and were classified as AIP 
stage 2 or 3 (Table 3.1). This number corresponds to 17.6% of the females (n=33) but only 
7.4% of the males (n=12). Within 6 month-old G4 mice, stage 4 was not observed. The details 
are given in Table 3.1. Interestingly, similar percentages of G4 mice developed spontaneous 
arthritis (Ranea et al., 2013) and lupus nephritis (unpublished data from Susan Müller & Saleh 
Ibrahim). 
 
Table 3.1 Summary of phenotyping: pancreatic histopathology of the fourth generation of  
four-way autoimmune-prone AIL 
  AIP stage Stage 
Gender Number 0 1 2 3 2+3(%) 
Male 163 83 68 11 1 7.4 
Female 188 53 102 32 1 17.6 
Both 351 136 170 43 2 12.8 
Pancreatic sections of 351 G4 mice (6 months old) were stained with Haematoxylin & Eosin, and 
evaluated applying a scoring system from 0 to 4 as further described in the methods section (2.2.1.2.1). 
AIP, autoimmune pancreatitis. 
 
 
As previously described, histological analyses of H&E stained sections of pancreata 
from the fourth generation (G4) AIL mice clearly showed that these mice developed 
pancreatic lesions at the age of 6 months (Figure 3.1). 
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Figure 3.1 Representative Haematoxylin & Eosin–stained histological sections of the pancreas in 
G4 Mice. 
Pancreatic sections of G4 mice were stained with Haematoxylin & Eosin (original magnification X- 
200). Histopathological findings of pancreatic lesions in G4 mice are ranging from stage 0 (A) to 3 
(D). (A) Healthy pancreas; stage 0. (B) Preserved exocrine and endocrine pancreas. One larger duct 
shows a minimal lymphocytic infiltration of the sub-epithelial layer (arrow); stage 1. (C) Moderate 
periductal lymphocytic infiltration; beginning destruction of acinar tissue; stage 2. (D) Severe 
periductal inflammation with moderate parenchymal destruction; stage 3. 
 
 
In accordance with previous studies (Fitzner et al., 2009; Qu et al., 2002; Sorg et al., 
2008), immunohistochemistry studies revealed that CD4+ and CD8+ T lymphocytes were 
predominantly found in pancreatic inflammatory lesions. Furthermore, CD45R (B220+) B-
lymphocytes and few F4/80-expressing cells (macrophages) were observed in pancreas 
(Figure 3.2). While these findings are comparable to histopathological changes in human AIP, 
fibrosis was minimal and only restricted to stage 3 of the disease. 
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Figure 3.2 Immunohistochemical analysis of leukocytes infiltration within the mouse pancreas 
(autoimmune pancreatitis stage 2). 
Tissue sections were stained with the ABC staining kit, using primary antibodies against (A) CD4,  
(B) CD8 (T lymphocytes), (C) F4/80 (macrophages), and (D) CD45R (B220; B cells). Note the 
pronounced cellular infiltration within the focal inflammatory lesions (original magnification x100). 
 
Since the inflammatory lesions in kidney, lymph nodes and spleen of MRL mice have 
been broadly reported (Jabs et al., 2001; Matsumoto et al., 2003; Uchida et al., 2002; J.-Q. 
Yang et al., 2004), the tissues of these organs were preserved for further histopathological 
examinations to evaluate the general signs of health and the possibilities of other diseases 
associated with AIP. 
3.2 Identification of Quantitative Trait Loci for Spontaneous AIP 
The genetic control of susceptibility to AIP was analyzed by an association study 
performed with the software package R-HAPPY. It determines the statistical significance of 
genetic loci based on ANOVA tests (Table 3.2). Empirical significance levels were assessed 
by 1000 permutations. A cut-off of 0.001 in the empirical P value, equivalent to one false 
positive per 1,000 associated SNPs, was defined and those SNPs above this threshold were 
considered significant. Empirical P values < 0.01 were considered suggestive. Plots of whole 
genome linkage map for autoimmune pancreatitis are represented in Figure 3.3 and Figure 3.4 
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that include details on chromosomes 2, 4, 5 and 6. Five QTLs were identified with logarithmic 
P values > 3, which were linked to the severity of AIP. Correspondingly, the first QTL was 
mapped on chromosome 2 (peak in rs6222797; ~32.94 Mbp CI). The next two QTLs were 
mapped to chromosome 4 (one peak in rs3676928; ~ 41.31 Mbp CI and the other peak in 
rs6287606; ~9.38 Mbp CI), another one was located on chromosome 5 (peak in rs3667334; ~ 
42.74Mbp CI) and finally one was mapped to chromosome 6 (peak in rs3695724; ~ 60.30 
Mbp CI) (Table 3.2, Figure 3.3 & Figure 3.4). Logarithmic P values of these five QTLs 
(subsequently termed AIP1-5) varied from 3.2 to 5.4. The mean confidence interval of each 
QTL was approximately 12 cM. Although a clear sex effect on the AIP pathological 
phenotype was observed (Table 3.1), analysing the genotyping data with sex as a co-variant 
showed no sex-effect or X-linked QTLs in these mice. Similar observation in the model of 
collagen-induced arthritis (Bauer et al., 2004) revealed that the effect of X-linked genes may 
be too small to be verified using this approach. 
Table 3.2 Summary of QTLs controlling AIP 
QTL Chr. Peaks (Mbp) a CI (Mbp) - log P b  Overlapping 
autoimmunity QTL c 
AIP1 2 64.9, 74.7 56.3 to 81.9 4.4 EAE21 
AIP2 4 18 7.1 to 32.3 3.2 Aaom1, Lxw1 
AIP3 4 82.4, 103.6 81.3 to 120.7 3.2 Sle2, Adaz1, Agnm2, 
Pgia27, Psds1 
AIP4 5 83.5 74.8 to 96.6 3.5 Cdcs10 
AIP5 6 121.2 111.2 to 133.9 5.4 Cia3 
The table presents all QTLs found significant by 1000 permutations, their chromosomal location, as 
well as their overlap with known autoimmunity QTL. The log P value presents the likelihood of 
observing the effect by chance as indicated by a single run of HAPPY. 
AIP, autoimmune pancreatitis; QTL, quantitative trait loci; CI, confidential interval; MbP, mega base 
pair; Chr., chromosome. 
 
a. Position according to the NCBI Build 37 
b.	  -­‐log P value of the association. 
c. QTLs retrieved from MGI database. 
    (http://www.informatics.jax.org/searches/allele_form.shtml) 
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The highest logarithmic P values were observed for two QTLs controlling AIP on 
chromosomes 2 and 6 (Table 3.2). The details of these QTLs are highlighted below (Figure 
3.3). 
 
 
 
 
Figure 3.3 Whole genome linkage map for spontaneous autoimmune pancreatitis I (detailed on 
chromosomes 2 and 6). 
Plots of autoimmune pancreatitis QTLs, on full genome (A), chromosome 2 (B), and chromosome 6 
(C). Log-likelihood values were determined using HAPPY. Logarithmic P values are presented on the 
y-axis in relation to positions of the marker loci (in megabases) along the chromosome, which are on 
the x-axis. Confidence intervals and flanking markers of the QTLs are indicated. 
 
 
 
3.3 Selected Candidate Genes 
Although a fine mapping of the QTLs still has to be accomplished, a first search for 
possible candidate genes was performed. Therefore, we focused on the two QTLs with 
logarithmic P values higher than 4, which are located on chromosomes 2 and 6 (Table 3.3). 
The most promising findings in these two chromosomes, including their position and SNPs 
found next to the peaks of the QTLs are summarised in Table 3.3. Moreover, details of SNPs 
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found next to the peaks of AIP QTLs (AIP1 and AIP5 QTLs) are given in Table 3.4. 
Subsequently, these potential candidate genes are discussed in detail in the next chapter. 
 
Table 3.3 Selected candidate genes of AIP QTLs in chromosomes 2 and 6 
QTL Chr. Genea Description Position 
(Mbp)b 
SNP next 
to peak of 
QTL 
Distance to 
peak of 
QTL (Mbp) 
AIP1 2 Hnrnpa3 Heterogeneous nuclear 
ribonucleoprotein A3 
 
75.5 rs13476580 0.8 
AIP1 2 Nfe2l2 Nuclear factor, erythroid 
derived 2, like 2 
 
75.5 rs13476581 0.8 
 
AIP1 2 Ssb Sjogren syndrome  
antigen B 
 
69.7 rs6222797 4.8 
 
AIP1 2 Ubr3 Ubiquitin protein ligase E3 
component n-recognin 3 
 
69.7 rs6222798 4.8 
 
AIP5 6 Clec4a2 C-type lectin domain 
family 4,member a2 
 
123.1 rs3695724 1.9 
 
AIP5 6 Pparg peroxisome proliferator 
activated receptor gamma 
 
115.4 rs3695724 5.8 
 
The table shows the candidate genes of the AIP 1 and AIP5 QTLs (with the highest logarithmic P 
values varied from 4.4 to 5.4) as well as their chromosomal location and position. 
AIP, Autoimmune pancreatitis; QTL, quantitative trait loci; Chr., chromosome; Mbp, mega base pair; 
SNP, single nucleotide polymorphism. 
 
a. Genes retrieved from MGI database. 
    (http://www.informatics.jax.org/searches/allele_form.shtml)  
b. Position according to the NCBI Build 37 
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Table 3.4 SNPs next to the peaks of AIP QTLs on chromosomes 2 and 6 
QTL Chr. SNP a Position (cM).b Position (bp) c - log P d 
AIP1 2 rs6222797 32.94 65119051 4.44 
AIP1 2 rs13476553 33.72 66967901 4.25 
AIP1 2 CEL.2_73370728 * 37.01 73314518 4.36 
AIP1 2 rs13476580 38.05 74881866 4.38 
AIP5 6 rs13478977 56.71 112524461 4.12 
AIP5 6 rs6393943 57.60 114407245 4.71 
AIP5 6 rs6401637 58.19 116090323 4.04 
AIP5 6 mCV23042866** 58.68 116756729 5.39 
AIP5 6 rs13478997 59.49 118072426 5.32 
AIP5 6 rs3695724 60.30 120007151 5.47 
AIP5 6 rs13479006 61.31 121299359 4.94 
AIP5 6 gnf06.122.747* 62.25 124006411 4.42 
AIP5 6 rs13479014 63.00 125048587 4.40 
AIP5 6 CEL.6_130920075* 65.36 130188076 4.34 
AIP5 6 rs3722480 66.29 131308308 4.10 
AIP, Autoimmune pancreatitis; QTL, quantitative trait loci; Chr., chromosome; SNP, single nucleotide 
polymorphism; bp, base pair; cM, centimorgan. 
a. SNPs symbols and description retrieved from MGI database. 
    (http://www.informatics.jax.org/searches/allele_form.shtml) 
b. Position retrieved from Ensembl. 
    (http://www.ensembl.org/Mus_musculus/Location) 
c. Position according to the NCBI Build 37 
    (http://www.ncbi.nlm.nih.gov/snp/?term). 
d. -­‐log P value of the association. 
* Position according to (http://www.well.ox.ac.uk/flint-old/distrib/chr6.build37.map)  
** Identical marker as rs30223567 
 
The next three AIP QTLs were mapped on chromosomes 4 (n=2) and 5 (with 
logarithmic P values of 3.2 ≥ 3.5) (Table 3.2 and Figure 3.4). The details of these QTLs and 
other overlapping autoimmunity QTLs are summarized in the Table 3.5 and Table 3.6. 
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Figure 3.4 Whole genome linkage map for spontaneous autoimmune pancreatitis II (detailed on 
chromosomes 4 and 5). 
Plots represent autoimmune pancreatitis QTLs on full genome (A), chromosome 4 (B), and 
chromosome 5 (C). Log-likelihood values were determined using HAPPY. Negative logarithmic P 
values are presented in relation to positions of the marker loci along the chromosome (cM, 
centimorgan). The x-­‐axis represents position in Mbp and the y-­‐axis shows -­‐log P value of the 
association.  
 
Table 3.5 SNPs next to the peaks of AIP QTLs on chromosomes 4 and 5 
QTL Chr. SNP a Position (cM)b Position (bp)c -log P d 
AIP2 4 mCV22939387 8.34 15394344 3.22 
AIP2 4 rs6287606 9.39 18118213 3.25 
AIP3 4 rs3676928 41.31 82765182 3.26 
AIP3 4 rs13477860 49.53 97344236 3.21 
AIP3 4 rs13477883 52.32 103962063 3.23 
AIP4 5 rs3667334 42.75 83042043 3.47 
Chr.; chromosom, SNP; single nucleotide polymorphism, cM; centi morgan, bp; base pair  
a. SNPs symbols and description retrieved from MGI database. 
    (http://www.informatics.jax.org/searches/allele_form.shtml) 
b. Position retrieved from Ensembl. (http://www.ensembl.org/Mus_musculus/Location) 
c. Position according to the NCBI Build 37 (http://www.ncbi.nlm.nih.gov/snp) 
d. -­‐log P value of the association. 
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3.4 AIP QTLs Overlap with QTLs for Other Autoimmune Diseases 
Data from Table 3.2 demonstrates that some of the newly identified AIP QTLs 
overlapped with known arthritis and lupus QTLs, e.g. AIP1 with EAE21 on chromosome 2, 
AIP3 with Sle2 and Psds1 on chromosome 4, and AIP5 with Cia3 on chromosome 6 (McIndoe 
et al., 1999; Santiago-Raber et al., 2007). The details of these QTLs are given in Table 3.6. 
 
Table 3.6 Overlapping newly indentified AIP QTLs in G4 mice with autoimmunity QTLs 
QTL Chr. Overlapping 
QTLa 
Description Position 
(Mbp)b 
SNP next to 
peak of QTLc 
Distance to 
peak of QTL 
(Mbp) 
AIP2 4 Aaom1 Autoimmune aoritis in 
MRL mice 1 
24.3-
46.3 
mCV22939387 6.3 
AIP2 4 Lxw1 Lupus BXSB x NZW 1 25.6 rs6287606 7.5 
AIP3 4 Sle2 Systemic lupus 
erythmatosus 
susceptibility 2 
82.8 rs3676928 0.1 
AIP3 4 Adaz1 Anti-dsDNA antibody 
production in NZM 1 
100.1 
 
rs13477860 2.76 
AIP3 4 Agnm2 Autoimmune 
glomerulonephritis in 
MRL 2 
118.4 
 
rs13477883 14.4 
AIP3 4 Pgia27 Proteoglycan induced 
arthritis 27 
87.1 rs3676928 4.7 
AIP3 4 Psds1 Psoriasis-like skin 
disease severity 1 
76.66 rs3676928 6.1 
AIP4 5 Cdcs10 Cytokine deficiency 
colitis susceptibility 10 
93.06 rs3667334 9.8 
The table provides details of overlapping autoimmunity QTLs with AIP QTLs (termed as AIP 2, 3, 4 
with the highest -log P value of 3.2 to 3.5), their chromosomal location and position. 
AIP, Autoimmune pancreatitis; QTL, quantitative trait loci; SNP, single nucleotide polymorphism; 
Mbp, mega base pair. 
a. QTLs symbols and description retrieved from MGI database. 
    (http://www.informatics.jax.org/searches/allele_form.shtml)  
b. Position retrieved from Ensembl (http://www.ensembl.org/Mus_musculus/Location)  
c. Position according to the NCBI Build 37 
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3.5 Detection of Immune Response Phenotypes 
To identify immune cells associated with AIP, flow cytometry-based phenotypic 
analysis was performed on spleenocytes of G4 mice (n=351) and parental strains (n=54). The 
percentages of T cells and their subpopulations, B cells and DCs were determined using 
specific surface markers. Tregs and T helper subtypes were determined by immunostaining for 
intracellular markers. The mean values of the percentages of subpopulations are summarised 
in Table 3.7. 
Table 3.7 Summary of immune cell phenotypes of mice splenocytes detected by flow cytometry 
Subpopulation              Mean ± SEM* Description 
 G4 Mice Parental Strains  
CD3+ CD4+ 15.68 ± 5.45 21.16 ± 6.918 T helper cells 
CD3+ CD4- 9.97 ± 4.15 13.17 ± 9.327 T cells 
CD3+ CD8+ 8.48 ± 4.05 11.14 ± 8.897 T suppressor/cytotoxic lymphocyte 
CD3+ CD8- 17.18 ± 5.61 23.19 ± 7.146 T cells 
CD4+ CD8+ (DP) 0.57 ± 0.36 0.44 ± 0.711 Doubel positive T cells  
CD4-CD8- (DN) 35.01±16.32 47.29 ± 8.772 Double negative leukocytes  
CD8+ B220+ 19.07 ± 6.40 0.60 ± 0.828 T cells/ T cytotoxic/suppressor  
CD4+ B220+ 0.80 ± 0.45 1.13 ± 1.561 T cells/ T helper 
CD44+ CD69+ 0.40 ± 0.65 0.79 ± 0.513 Memory T cells/effector Tcells 
CD44+ CD62L+ 16.21±10.12 12.48 ± 5.127 Naive/memory/effector T cells 
CD44+ CD8+ 4.76 ± 3.34 4.84 ± 2.366 Memory CD8 T cells/age 
CD8+ CD62L+ 6.18 ± 3.79 9.69 ± 7.878 Memory CD8 T cells/central in pb 
CD8+CD69+ 0.37 ± 0.35 0.67 ± 0.790 Activated CD8 cells 
CD44+CD4+ 12.97 ± 4.48 15.40 ± 7.153 Memory CD4 T cells 
CD4+CD69+ 0.31 ± 0.59 0.60 ± 0.319 Tregs  
CD62L+CD4+ 7.72 ± 4.66 9.30 ± 6.884 T helper / Th1/Th2 differentiation  
CD19+ CD69+ 0.28 ± 0.19 0.16 ± 0.117 B cells, Activated B cells (B act) 
CD19+ CD69- 37.34 ± 11.26 16.35 ± 6.958 B cells 
CD19+ CD86+ 0.43 ± 0.69 0.39 ± 0.343 B cells, B act  
CD19+ MHC classII+ 33.02 ± 11.53 11.85 ± 4.804 B cell 
CD69+ MHC classII+ 0.27 ± 0.20 0.21 ± 0.126 APC,Dcs and B cells  
CD86+ MHC classII+ 0.46 ± 0.82 0.64 ± 0.628 APC 
CD11c+ PDCA1+ 0.74 ± 0.46 0.49 ± 0.377  Dendritic/plasmacytoid dendritic cells  
CD11c+ CD86+  0.33 ± 0.35 0.16 ± 0.170 Dcs 
CD11c+ PDCA1- 1.90 ± 1.00 2.02 ± 1.285 Dcs 
CD11c- PDCA1+ 2.63 ± 3.70 2.78 ± 5.774 Plasmacytoid dendritic cells (PDcs) 
CD86+ PDCA1+ 0.48 ± 0.62 0.22 ± 0.288 PDcs 
CD4+ FoxP3+ 0.45 ± 0.42 0.06±0.038 Tregs (helper) 
CD8+ FoxP3+ 0.14 ± 0.14 0.04±0.036 Tregs(cytotoxic or suppressor ) 
CD4+ IL17+ 0.31 ± 0.29 0.02 ± 0.023 T helper 17 
CD4+ IFN-γ+ 0.51 ± 0.63 0.04 ± 0.032 T helper 1 
CD4+ IL4+ 0.21 ± 0.20 0.31 ± 0.182 T helper 2 
*Results are expressed as mean ± SEM of total splenocytes (×106) of G4 four-way AIL mice (n=351) 
and parental strain (MRL,BXD, NZM,CAST mice)(n=54) 
CD; Cluster of differentiation, DP; Double positive, DN;double negative, FoxP3;forkhead-box-protein 
P3, PDCA-1; plasmacytoid dendritic cell antigen-1, APC; Antigen-presenting cells, MHC classII; 
major histocompatibility complex class II, Tregs; Regulatory T cells, IL17;interleukin 17, IFN-γ; 
interferon gamma, IL4; interleukin 4, Dcs; dendritic cells. 
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The ratio of CD3+CD4+ T cells to CD3+CD8+ T cells (CD4/CD8 ratio) was also 
calculated. The CD4/CD8 ratios of splenic T lymphocytes of 6-month-old mice were 1.849 in 
G4 mice and 1.899 in parental strains (Table 3.7). 
We found a significant positive correlation between autoimmune pancreatitis and T 
helper cells (CD4+ ), activated T helper (CD4+ CD44+) in 6 months G4 old mice (significant 
with Benjamini Hochberg FDR <0.05) (Table 3.8). Additionally, a negative correlation was 
abserved between AIP and CD8+ CD44- phenotype. 
 
Table 3.8 Correlation between AIP and splenic B and T Lymphocytes 
phenotype correlation coefficient* P-value corrected P-value** 
CD4+ CD44+ 0.19 0.0003 0.0153 
CD4+ CD69+ 0.16 0.0030 0.0436 
CD8+CD44- -0.16 0.0023 0.0436 
* Spearman`s rho 
** Benjamini Hochberg FDR<0.05 
 
 
These findings are in line with numerous studies showing that T cells play role in 
development of acute and chronic inflammatory diseases. In particular, CD3+CD4-CD8- 
(double negative) T cells and their potential pathogenic role in inflammation and 
autoimmunity (D'Acquisto & Crompton, 2011) might be of interest. 
An early development of pancreatitis with abundant infiltration of activated Foxp3-
positive cells was observed in MRL/Mp mice treated with poly I:C (Koyabu et al., 2013), 
suggesting that Tregs may be involved in the development of pancreatitis in these mice. We 
asked whether QTL controlling activated and/ or Treg cells overlapped with AIP QTLs. 
Interestingly, screening for phenotype/genotype linkage in chromosome 2 displayed 
overlapping for all of 12 SNPs that were significant for AIP1 QTL. High logarithmic P values 
(3.2 ≥ 7.11) were observed for linkage between these SNPs and the following three 
phenotypes: CD4+ FOXP3+, CD8+ FOXP3+, CD8+ CD69+ (Figure 3.5). The table below 
illustrates the details of these SNPs (Table 3.9). 
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Table 3.9 SNPs on Chr 2 controlling AIP located in QTL of the three phenotypes (Tregs and 
activated Tcells) 
Marker a Position (cM) b CD4+FOXP3+ 
-log P c 
CD8+FOXP3+ 
-log P c 
CD8+CD69+  
-log P c 
rs13476530 30.374 7.11 6.47 4.55 
rs4223189 31.170 6.39 5.59 4.42 
CEL.2_63143553 32.000 5.62 4.57 4.90 
rs6222797 32.941 5.99 4.99 6.46 
rs13476553 33.723 6.77 5.52 6.37 
rs6381994 34.881 6.75 5.70 4.30 
rs3664661 36.188 6.38 5.34 3.80 
CEL.2_73370728 37.009 5.67 4.47 3.31 
rs13476580 38.053 5.04 4.08 4.07 
gnf02.076.311 39.169 4.90 4.07 5.27 
CEL.2_79237503 39.910 5.79 5.79 5.69 
rs3722345 40.600 4.95 4.94 6.02 
The updated list of SNPs located on AIP1 QTL showed overlapping for CD4+ FOXP3+, CD8+ FOXP3+ 
and CD8+CD69+ phenotypes on Chr2, as well as their position and -log P value. 
a. Position according to the NCBI Build 37 
b. Position retrieved from Ensembl. (http://www.ensembl.org/Mus_musculus/Location)  
c. -­‐log P value of the association. 
 
 
The first SNP in Table 3.9 (rs13476530) with the highest logarithmic P value (-log P 
value=7.11), additionally overlaps with four previously identified QTLs: Collagen-induced 
arthritis QTL 2 (Cia2), Collagen-induced arthritis QTL 4 (Cia4), Experimental allergic 
encephalomyelitis susceptibility 21 (Eae21) and Experimental allergic encephalomyelitis 
susceptibility 33 (Eae33). 
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Figure 3.5 Whole-­‐genome linkage map for AIP and Treg markers/activated T cells as covariates 
in G4 
The figures show genotype/phenotype overlapping of QTLs controlling AIP with (A) CD4+ FOXP3+, 
(B) CD8+ FOXP3+ and (C) CD8+ CD69+ phenotypes, which were used as covariates. Logarithmic p 
values are presented in relation to positions of the marker loci along the chromosome. The x-­‐axis 
represents position in Mbp and the y-­‐axis shows -­‐log P value of the association. 
 
In Figure 3.5/B a locus (rs6378343, 6:63823084bp, ~ 32.20cM, -log P value =4.9) 
overlaps with collagen-induced arthritis QTL 6 (Cia6 on Chr6:4464884-87426034). This 
region contains four genes, which support a previous suggestion that CD8+ T cell could play a 
protective role in some AID (Gravano & Hoyer, 2013; McKinney et al., 2010). These genes 
are CD8 antigen alpha chain (Cd8a on Chr6:71373427-71379171), CD8 antigen, beta chain 1 
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(Cd8b1 on Chr6:71322812-71337451), interleukin 23 receptor (Il23r on Chr6:67422932-
67491855) and interleukin 12 receptor beta 2 (Il12rb2 on Chr6:67291318-67376188). 
As it can be seen in Figure 3.5 A & B, two other peaks on Chr. 7 (SNP next to the peak: 
rs3699086, ~52.28cM, with -log P value = 7.38 and 4.98) and Chr. 9 (SNP next to the peak: 
rs3700596, ~43.49 cM, with -log P value = 8.97 and 5.63) linked to the CD4+ FOXP3+ and 
CD8+ FOXP3+ phenotypes as well. The most important findings in the region on Chr. 7 are 
summarized in Table 3.10. 
Table 3.10 QTLs or genes located next to the peak SNP (rs3699086) on chromosome 7  
Symbol a type Name Position (bp) b 
Il4ra  gene interleukin 4 receptor, alpha  125552282-125579472  
Il4ppq QTL IL4 producing potential  124914439-129217600  
Lat gene linker for activation of T cells  126363827-126369534 
Il18bp gene interleukin 18 binding protein  102015079-102018155 
Igsf6* gene immunoglobulin superfamily, member 6 121064067-121074530 
Eae26 QTL experimental allergic encephalomyelitis 
susceptibility 26  
115565687-115565775 
Cia7 QTL Collagen-induced arthritis QTL 7 85716387-112934612 
Idd27 QTL insulin dependent diabetes susceptibility 27 QTL 79376386-119886157 
Cd19 gene CD19 antigen 126408450-126414870 
QTL, Quantitative trait loci; bp, base pair. 
a. SNPs symbols and description retrieved from MGI database. 
    (http://www.informatics.jax.org/searches/allele_form.shtml) 
b. Position retrieved from Ensembl. 
    (http://www.ensembl.org/Mus_musculus/Location) 
*This gene is mapped to the inflammatory bowel disease 1 locus (Bates et al., 2000). 
 
There was a significant association between the locus (rs3700596:~ 43.49cM) on Chr.9 
and CD4+ FoxP3+ (-log P value = 8.975), CD8+ FoxP3+ (-log P value = 5.63). Interestingly, 
the T lymphocyte fraction gene (Tlf)8 maps also in this region (~ 52.24 cM), which shows 
association with autoimmune diabetes (Pearce, 1998; Pearce et al., 1995). 
In the next step, the results of immunophenotyping are checked in the same way for 
linkage between AIP QTLs and Th1, Th2 andTh17 phenotypes. Based on the role of IFN-γ, a 
pro-inflammatory cytokine released by Th1 cell, in the pathogenesis of autoimmune 
pancreatitis, a phenotype/genotype association analysis was performed. Our result in Figure 
                                                
8 http://www.informatics.jax.org/marker/MGI:109546 
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3.6 shows the overlap between AIP QTL and the region controlling CD4+ IFN-γ+ phenotype 
(Th1 cells) for the two following SNPs (both of them are in AIP2 QTL): 
• rs6287606 on Chr. 4 at 9.388 cM (-log P value = 9.01). The previously mapped 
QTLs in this region are and Lxw1 (lupus BXSB x NZW 1) and Aaom1 
(autoimmune Aortitis in MRL mice1). 
• mCV22939387 on Chr.4 at 8.341 cM (-log P value = 5.13), which overlaps 
with Nbwa2 (NZB and NZW autoimmunity 2 QTL) on Chr.4 at 34892515-
34892635 bp. This locus contains the interferon kappa gene (Ifnk) on Chr. 4 at 
35152056-35154005 bp. 
 
 
 
 
 
 
 
 
 
Figure 3.6 Whole-­‐genome linkage map for AIP and CD4+ IFN-γ+ phenotype as covariant.  
The plot shows relationship between AIP QTLs and Th1 marker as phenotype in G4 mice. The x-­‐axis 
represents position in Mbp and the y-­‐axis shows -­‐log P value of the association. 
As can be seen in Figure 3.7, the five SNPs (on Chr. 2) show overlapping for the region 
controlling CD4+ IL4+ (Th 2) phenotype: 
• rs13476530 at position 30.37 cM (-log P value = 3.22)  
• rs13476553 at position 33.72 cM (-log P value = 3.54) 
• gnf02.076.311 at position 39.17 cM (-log P value =3.62) 
• rs3722345 at position 40.60 cM (-log P value = 4.52)  
• and CEL.2_79237503 at position 39.90 cM (-log P value = 4.54). 
 
 
 
 
 
 
 
 
Figure 3.7 Whole-­‐genome linkage map for AIP and CD4+ IL4+ as a covariate in G4 mice 
Logarithmic P values are presented in relation to positions of the marker loci along the chromosome. 
The x-­‐axis represents position in Mbp and the y-­‐axis shows -­‐log P value of the association. 
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The phenotype/genotype association and overlapping between AIP QTLs and several 
other immunologic QTLs was checked and provided relevant information about possible 
mechanisms underlying QTLs function. In AIP5 QTL region, out of 16 SNPs with high 
logarithmic P values for AIP, five SNPs displayed overlapping for the region associated with 
CD4+ IL17+ phenotype, whereas in AIP2 QTL region overlap was observed for 2 of 5 SNPs 
that linked with AIP (Figure 3.8 and Table 3.11). As can be seen in Figure 3.8, the same two 
SNPs controlling Th1 phenotype show overlapping for the region controlling CD4+ IL17+ 
(Th17) phenotype as well. 
 
Table 3.11 SNPs on chromosomes 4 and 6 controlling AIP located in QTL and linked with  
CD4+IL17+ phenotype 
SNPs a Chr. Position b 
(cM)              (Mbp) 
-log P Overlapping 
autoimmune QTLs/Gene 
mCV22939387 4 8.341675 15.39 4.609 Nbwa2, Ifnk 
rs6287606 4 9.388400 18.12 4.987 Lxw1, Aaom1 
rs13479014 6 62.998 125.05 4.538 Cypr5,Dbm1, Ibdq2, Ltbr 
rs6389420 6 63.737 127.04- 4.440 Cd4,Cd69, Cypr5, Ibdq2, 
Il17ra  
rs3681620 6 64.536 128.00- 3.705 // 
CEL.6_130920075 6 65.362 130.19 3.786 Cia3, Foxj2, Foxm1, Irak2  
rs6339546 6 67.03 133.97 3.563 // 
The table presents the SNPs that showed genotype/phenotype overlapping for AIP 2 QTLs and AIP 5 
QTL and CD4+ IL17+ on Chr.6 with the highest -log P value as well as their position. QTL, quantitative 
trait loci; SNP, single nucleotide polymorphism; Mbp, mega base pair; cM, centimorgan. 
a. Position according to the NCBI Build 37 
b. Position retrieved from Ensembl. (http://www.ensembl.org/Mus_musculus/Location) 
c. -­‐log P value of the association. 
 
The most important findings in these regions in chromosomes 2 and 6 are listed in Table 
3.12. Interestingly, these two AIP QTLs that linked to CD4+IL17+ phenotype colocallized 
with the previously identified autoimmune QTLs, namely Cypr5, Cia3 and Ibdq2. Some genes 
in these intervals such as lymphotoxin B receptor gene (Ltbr), interleukin 17 receptor A gene 
(Il17ra), Cd4 antigen and Cd69 antigen might be suggested as candidate genes for this 
phenotype. 
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Table 3.12 QTLs and genes next to CD4+ IL17+ phenotype` peaks on chromosomes 4 and 6  
Symbol a Type Name Chr.b Position (bp) c 
Nbwa2 QTL NZB and NZW autoimmunity 2 4 34892515-34892635  
Ifnk gene interferon kappa 4 35152056- 35154005 
Lxw1 QTL lupus BXSB x NZW 1 4 25683240-25683429 
Aaom1 QTL autoimmune aoritis in MRL mice 1 4 24322299-46332776 
Cypr5 QTL cytokine production 5 QTL 6 127838217-127838360 
Dbm1 QTL diabetes modifier 1 QTL 6 78629504-121115387 
Ibdq2 QTL inflammatory bowel disease QTL 2 6 106005405-120916853 
Ltbr gene lymphotoxin B receptor gene 6 125306571-125313885 
Cd4 gene CD4 antigen; 6 124864692- 124888221 
Cd69 gene CD69 antigen 6 129267325-129275369 
Il17ra gene interleukin 17 receptor A  6 120463197-120483727 
Cia3 QTL Collagen-induced arthritis QTL 3 6 113347325-113347522 
Foxj2 gene forkhead box J2  6 122819914-122845366 
Foxm1 gene forkhead box M1 6 128362967-128375893 
Irak2 gene interleukin-1 receptor- associated kinase 2 6 113638467-113695009 
Chr.,chromosome; bp, base pair. 
a. SNPs symbols and description retrieved from MGI database. 
    (http://www.informatics.jax.org/searches/allele_form.shtml) 
b. Chr.; chromosome. 
c. Position retrieved from Ensembl. 
    (http://www.ensembl.org/Mus_musculus/Location) 
 
 
 
Interestingly, a single strong linkage to CD4+ IL17+ phenotype (as covariates in linkage 
mapping) was identified in region on Chr.18 (Figure 3.8) with the highest logarithmic P value 
in its peak for two SNPs: 
• rs3658163 (Chr.18:68661314 bp, ~ 34.776 cM) (-log P value = 9.614). One of 
the QTLs in this region is T helper cell response (Thcr)9 QTL (at position 
44997537-6864706 bp), which controls NKT cell homeostasis and T helper 
cell differentiation in murine (Zhang et al., 2003; Zhang et al., 2006). 
                                                
9 (http://www.informatics.jax.org/marker/MGI:3036489) 
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• rs3691542 (Chr.18:66474868 bp, ~ 33.864 cM) (-log P value = 9.337). A 
protein coding gene, interleukin 17B (Il17b)10 (Chr. 18: 61687935-61692537 
bp) is located also in this region. The protein encoded by this gene is a T cell-
derived cytokine that shares sequence similarity with IL17 (Shi et al., 2000). 
 
 
 
 
 
 
 
 
 
Figure 3.8 Whole-­‐genome linkage map for AIP and CD4+ IL17+ as covariate in G4 mice 
Logarithmic P values are presented in relation to positions of the marker loci along the chromosome 
and show relationships between QTLs and phenotype. The x-­‐axis represents position in Mbp and the 
y-­‐axis shows -­‐log P value of the association. 
                                                
10 (http://www.informatics.jax.org/marker/MGI:1928397) 
 
 Discussion  
53 
 
 
4 Discussion 
Autoimmune pancreatitis is a rare disease that primarily involves the pancreatic duct 
bile ducts with characteristic histopathological changes in the tissue (Adarichev, Nesterovitch 
et al., 2003). Some of the typical histopathological features of AIP are a storiform fibrosis, 
dense periductal and diffuse lymphoplasmacellular infiltrates, obliterative periductal fibrosis 
and the presence of numerous CD4 and CD8 lymphocytes (Klimstra & Adsay, 2004; Okazaki 
et al., 2000; Zamboni et al., 2004). 
Since the term “Autoimmune pancreatitis” was introduced (Yoshida et al., 1995), the 
field of AIP is extremely evolving. This relatively new entity has at least two subtypes:  
(a) lymphoplasmacytic sclerosing pancreatitis (LPSP; AIP type 1) with presence of IgG4-
posivite cells, (b) idiopathic duct-centric chronic pancreatitis (IDCP; AIP type 2) or AIP with 
supposed granulocyte-epithelial lesions (GEL) (Chari et al., 2010; Okazaki et al., 2010; 
Zamboni et al., 2004). Although AIP type 2 shares some common features with AIP type 1, 
i.e. obstructive jaundice, diffuse pancreatic enlargement on imaging studies and the excellent 
steroid responsiveness, they are considered to be two distinct clinicopathological entities 
(Kamisawa, Funata, Hayashi, Eishi et al., 2003). 
The pathoetiology of AIP is being extensively studied during the last decade. Some 
evidence suggests that in addition to ductal cells, acinar cells and their protein components are 
also targets of the immune-related inflammatory process that characterizes AIP. The most 
eminent finding are autoantibodies against trypsinogens (the cationic trypsinogen gene; 
PRSS1 and the anionic trypsinogen; PRSS2) (Gao et al., 2013; Witt et al., 2006), trypsin 
inhibitor PSTI (Pancreatic secretory trypsin inhibitor) (Asada et al., 2006) and autoantibodies 
against ubiquitin subunit (UBR2; a particular acinar protein) (Frulloni et al., 2009). Using 
immunoassay and gene expression analysis, Löhr et al. detected  autoantibodies against 
trypsinogen in AIP patients, which are useful to identify acinar cells and their secretory 
enzymes as a key target of the inflammatory process (Löhr et al., 2010). Beside the 
histopathological features of AIP, elevated autoantibodies against trypsinogens (PRSS1 and 
PRSS2) and trypsin inhibitor PSTI (Asada et al., 2006) in AIP patients may facilitate clinical 
diagnosis of AIP and help to further distinguish it from non-AIP CP. Although an association 
between PRSS1 gene mutations and AIP has been reported for the first time (Gao et al., 2013), 
it is possible to hypothesis that AIP is a separate disease entity with its own susceptibility 
genes and that the genetic basis of AIP differs from non-AIP forms of CP. 
 Discussion  
54 
 
 
4.1 Four-ways Autoimmune-prone Advanced Intercross Line (AIL) Progeny 
The most important goal of this study was to generate an outbred intercross mouse line, 
a four-ways autoimmune-prone advanced intercross line (AIL), the progeny of which 
represents a large family with higher incidence of common autoimmune diseases. Therefore, 
we took the advantage of the MRL/Mp mouse model of AIP (established by Kanno et al), the 
lupus-prone NZM2410/J strain, the arthritis-prone BXD2/TyJ mice and CAST/EiJ to generate 
F1 hybrids and future generations with high levels of heterozygosity and to identify genes 
contributing to autoimmune diseases susceptibility using QTLs mapping. This part of the 
project had started in 2008 at the University of Rostock and then continued in Lübeck at the 
UKSH. The sixteenth generation (G16) of this line is available now. Although we focused 
particularly on the genetic basis of AIP and its pathophysiology in this study, it should be 
mentioned that our established four-way autoimmune-prone AIL mice were also used in 
parallel in other studies to identify loci contributing to arthritis, epidermolysis bullosa 
acquisita and systemic lupus erythematosus. Taken together, data from G4 mice that 
developed autoimmune diseases led to the identification of a number of previously unknown 
QTLs that are located on different murine chromosomes (Asghari et al., 2011; Ludwig et al., 
2012; Ranea et al., 2013). Ongoing fine mapping studies at the level of the G16 aim at 
reducing the size of the QTL and will be completed in 2014. 
4.2 Development of AIP 
In order to monitor development of spontaneous AIP in parental and G4 mice, 
histological and immunohistochemical analyses of pancreas sections were performed. 
Histopathological examinations clearly showed that the G4 mice spontaneously developed 
pancreatic lesions with an incidence of 7.4 % in male and 17.6 % in female mice at the age of 
6 months (Table 3.1). These results match those observed in earlier studies, which specified as 
a typical feature of the MRL/Mp mouse model of AIP that the incidence and severity of the 
disease are significantly higher in female mice. The onset of the disease is earlier than in male 
individuals (Kanno et al., 1992; Qu et al., 2002; Sorg et al., 2008; Yu, Wester-Rosenlöf et al., 
2009). The histological changes reported in the present study are also in agreement with 
previous studies, which indicated that histopathological changes, specifically 
lymphoplasmacytic infiltrates were more severe in female mice then male individuals (Figure 
3.1). Similar results were observed for organ destruction as well. 
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It has previously been thought that CD4+ T lymphocytes (compared with CD8+ T 
lymphocytes) are critical in mediating AIP pathogenesis (Klöppel et al., 2003; Zandieh & 
Byrne, 2007). This interpretation contrasts with that of Li et al. (2011) who reported a case of 
AIP with a significant CD8+ infiltration and an absence of CD4+ T lymphocytes in the 
pancreas and surrounding organs, including the duodenum (Li et al., 2011). On the other hand, 
several studies have shown that infiltrating cells in AIP cases predominantly consisted of 
CD4+ T lymphocytes with few detectable CD8+ T lymphocytes and B lymphocytes (Kim et 
al., 2004; Klöppel et al., 2003). The results of the current study also support the findings of 
Sorg et al. in 2008, who have noted the importance of infiltrated CD4+ and CD8+ T 
lymphocytes, plasma cells, granulocytes and macrophages (Sorg et al., 2008) for 
characterizing AIP in MRL/Mp mice. 
Pancreatitis in G4 mice was characterized by inflammatory cell infiltrates with 
destruction of acinar cells and replacement by fibrous tissue. Characterization of the 
inflammatory cells demonstrated that a high percentage of organ-infiltrated inflammatory cells 
were CD4+ and CD8+ T lymphocytes (Figure 3.2). However, granulocytes and macrophages 
were also detectable, as has previously reported by Sorg et al. (Sorg et al., 2008). Moreover, 
immunohistochemical examination revealed that CD4+ T cells and macrophages mediate 
pancreatic inflammatory lesions. The histopathology of the pancreatitis in this animal model 
mimics human autoimmune pancreatitis of subtype 1. 
4.3 QTL Analysis 
Until recently, the genetic basis of AIP has not been systematically investigated. This 
might be due to the limited availability of suitable animal models for the disease. Despite low 
incidence of the disease, identification of susceptible and resistance genes of AIP could be 
important to achieve new diagnostic markers and alternative treatment strategies of human 
AIP and for further studying the immunopathogenesis of this disease. 
In order to understand the genetic basis of AIP, a full genome scan was performed for 
330 G4 four-way AIL mice using a set of 1400 SNPs to identify novel QTLs linked to AIP. 
The first genotype/phenotype association analysis that was performed in these mice led to the 
mapping of five AIP -associated QTLs (Asghari et al., 2011). The following five QTLs, so 
called AIP1-5, were identified with support confidence intervals of ~ 12 cM, which still 
contain hundreds of genes. AIP1-5 OTLs were mapped to mouse chromosomes 2, 4 (n=2), 5 
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and 6 with logarithmic P values varying from 3.2 to 5.4 (Table 3.2). It is interesting to note 
that all identified loci in this study overlap partially, but not completely, with known loci 
previously linked to arthritis (Cia2, Cia4) and lupus erythematosus, suggesting similarities 
between the primary susceptibility genes of AIP and other autoimmune diseases. On the other 
hand, in a parallel study in G4 mice, Ludwig et al. reported a maximum disease severity 
associated with QTLs of epidermolysis bullosa acquisita on chromosomes 1, 15 and 19, none 
of which overlapped with the newly identified QTLs of the AIP (Ludwig et al., 2012). The 
other five loci, contributing to arthritis, that were identified on chromosomes 3, 7, 13, 18, and 
X in G4 mice didn´t also overlap with AIP QTLs (Ranea et al., 2013). A possible explanation 
for this might be that AIP is a separate disease entity with its own susceptibility genes, and 
that the genetic basis of AIP differs from other autoimmune diseases. 
4.3.1 AIP1 QTL and Its Candidate Genes 
The newly identified AIP1 QTL (Table 3.2) was mapped on chromosome 2 with 
confidential interval between 56.3 to 81.9 Mbp. Two peaks of this QTL, one at 64.9 Mbp 
(-log P value = 4.4) and other at 74.7 Mbp ( -log P value = 4.3) (Table 3.4) are relatively close 
to the peak of the well known QTL susceptibility to experimental allergic encephalomyelitis 
susceptibility 21 (EAE21). EAE21 is one of 10 identified QTLs that control susceptibility or 
clinical signs of experimental allergic encephalomyelitis (EAE) in the mouse genome 
(Butterfield et al., 2000). Multiple sclerosis (MS) is the most important inflammatory disease 
of the central nervous system (CNS), which involves autoimmune responses to myelin 
antigens. The role of T cells in the pathogenesis of the disease, particularly CD4+ T cells that 
secrete IL17, has been recently studied in experimental autoimmune encephalomyelitis 
(EAE), an animal model for MS, as well as other AID (Fletcher et al., 2010). In a study that 
was performed by Butterfield et al., it has been suggested that the severity and location of 
CNS lesions in EAE are genetically controlled. Moreover, the genetic component controlling 
the character and severity of the lesions can also be influenced by sex (Butterfield et al., 
2000). 
There are a number of genes found in this locus (Table 3.3), some of which are close to 
the peaks of QTL. Despite having many potential candidate genes in this locus on 
chromosome 2, some of them are most likely the main susceptibility candidate genes. These 
genes are HnRNP A3, Nuclear factor erythroid derived 2 like 2, Sjogren 's syndrome antigen B 
and Ubiquitin protein ligase E3 component n-recognin 3 (Ubr3). These genes are involved in 
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pathways that play a significant role in the regulation of inflammatory process. Although a 
fine mapping of the QTLs still has to be accomplished, a first search for possible candidate 
genes was already performed. Therefore, we focused on the two QTLs with higher logarithmic 
P values (˃4), which are located on chromosomes 2 and 6 (Table 3.3). The most promising 
findings in these two chromosomes including their position and SNPs next to the peaks of 
QTLs are summarized in Table 3.3. Subsequently, these potential candidate genes are 
discussed in detail in this chapter. Moreover, details of SNPs next to the peaks of AIP QTLs 
(AIP1 and AIP5 QTLs) are given in Table 3.4. 
4.3.1.1 Heterogeneous Nuclear Ribonucleoprotein A3 Gene (Hnrnpa3) 
The first candidate gene in this region (AIP1 QTL) is Hnrnpa3 (Chr2:75659261-
75669407 bp, ~ 44.75 cM). Ribonucleoprotein particles of the Heterogeneous nuclear 
ribonucleoproteins (hnRNPs), which belong to the spliceosomal macromolecular group, are 
involved in various cellular functions, including precursor of mRNA processing (actively 
participating in pre-mRNA metabolism), transcriptional regulation and DNA recombination 
(He & Smith, 2009). For unknown reasons ribonucleoprotein particles (RNP) are frequently 
targeted by autoantibodies and thus play a significant role in a variety of human systemic 
autoimmune diseases. They are also associated with the pathophysiology of disease 
(Süleymanoĝlu, 2003), which makes them valuable prognostic markers in terms of molecular 
epidemiology and pathogenesis of autoimmunity. Particularly, HnRNP A3 has been reported 
to bind to the 3′-UTR region of the cyclooxygenase-2 (Cok et al., 2004) and the tumour 
necrosis factor-α gene (Rousseau et al., 2002), suggesting a link to the regulation of 
inflammatory responses. Some members of the hnRNP family are involved in systemic 
autoimmune diseases such as lupus erythematosus and represent important autoantigens 
(Fritsch-Stork et al., 2006; Süleymanoĝlu, 2003). Although very little is known from the 
literature regarding the specific role of Hnrnpa3 or its correlation with AIP, the present 
findings seem to be consistent with other research that has implicated the Hnrnpa2 protein in 
lupus erythematosus (Fritsch-Stork et al., 2006; Süleymanoĝlu, 2003). Therefore, it can be 
suggested that Hnrnpa3 (as a major T -cell autoantigen) may be directly involved in the 
development of AIP. 
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4.3.1.2 Nuclear Factor, Erythroid Derived 2, Like 2 Gene (Nfe2l2; Nrf2) 
Nuclear factor erythroid derived 2 like 2 (Nfe2l2 or Nrf2) is the next candidate gene in 
this region (Chr2: 75675513-75704641 bp, ~ 44.75 cM). The corresponding protein is the 
main transcription factor of the antioxidant response pathway. It has been reported that Nrf2-
null mice develop a lupus-like autoimmune syndrome, which is characterized by multiorgan 
inflammatory lesions with a marked female predominance, appearance of anti-double-
stranded DNA antibodies and intravascular deposition of immunoglobulin complexes in blood 
vessels. Moreover, an enhanced proliferative response of CD4+ T cells with altered ratios of 
CD4+ and CD8+ cells and increased oxidative lesions in tissues of Nrf2-null mice have been 
observed (Ma et al., 2006; Yoh et al., 2001). 
Regarding the biological function of Nrf2, Singh et al. stated that Nrf2 binds to the 
antioxidant response element (ARE) in the regulatory regions of multiple genes involved in 
the antioxidant defence system (Singh, Vrishni, Singh, Rahman, & Kakkar, 2010). Briefly, 
this function initiates in response to electrophilic and oxidative stress. Following its activation, 
Nrf2 binds to ARE, which consequently upregulates a series of antioxidant and detoxifying 
genes. Thus silencing of Nrf2 may open a new window in treatment of oxidative stress-
mediated diseases such as cancer. It has been shown that significant antioxidant functions, 
which are involved in the control of peripheral lymphocyte homeostasis and autoimmune 
surveillance, can be mediated by Nrf2 (Ma et al., 2006; Yoh et al., 2001). 
4.3.1.3 Sjogren´s Syndrome Antigen B Gene (Ssb) 
Sjogren syndrome antigen B (Ssb) (Chr2:69861562-69871786 bp, ~40.95 cM) is another 
candidate gene that located in the same genomic region as AIP 1 QTL (Table 3.2) SSb is an 
important gene associated with Sjogren's syndrome. A common finding in patients with 
Sjogren´s syndromeare is antinuclear antibodies, which are directed against ribonucleoprotein 
SSB (autoantigen La) (Routsias & Tzioufas, 2010). The potential link between AIP 
susceptibility and SSB is interesting since sialadenitis represents the most frequent association 
of AIP (Klöppel et al., 2003). However, it should be noted that human sialadenitis associated 
with AIP differs from Sjogren´s syndrome in some important regards, i.e. lack of anti-
SSA/SSB autoantibodies and prominent infiltration of IgG4-positive cells (Okazaki et al., 
2010). Moreover, an association between autoantibodies to Ro/SSA and La/SSB with DR3, 
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DQA and DQB alleles has been reported in different studies (Bolstad & Jonsson, 2002; Fei et 
al., 1991). 
4.3.1.4 Ubiquitin Protein Ligase E3 Component n-Recognin 3 Gene (Ubr3) 
The last candidate gene in this region is ubiquitin protein ligase E3 component n-3 
Recognin (UBR3). Ubr3 is a protein-coding gene that belongs to the Ubr1 family of E3 
ubiquitin-protein ligases, acting as a component of the N-end rule pathway. Deficiency of the 
related protein Ubr1 has been shown to cause Johnson-Blizzard syndrome, an autosomal-
recessive disorder associated with intrauterine-onset destructive pancreatitis, congenital 
exocrine pancreatic insufficiency, malformations and mental retardation (Zenker et al., 2005). 
Furthermore, an autoantibody against the plasminogen-binding protein of Helicobacter pylori, 
which is present in 95% of AIP patients, has been suggested to cross-react with UBR2, an 
enzyme highly expressed in pancreatic acinar cells (Frulloni et al., 2009). As noted above, 
similarity between UBR3 and UBR2, which acts as a potential autoantigen in AIP and 
association with Sjogren’s syndrome, is of interest. Therefore, the role of UBR proteins in the 
pathogenesis of the CP and specifically AIP required further investigation. Follow-up studies 
in this field should include detection of autoantibodies and UBR3-reactive T-cells in AIP 
models and patients. 
Since AIP is a complex disease controlled by many factors, it is reasonable to speculate 
that genes controlling other immune phenotypes, such as antibodies and T cell subsets, might 
affect AIP development. Thus, the four genes mentioned above could be considered as 
candidate genes for AIP1 QTL. 
4.3.2 AIP5 QTL  
The next AIP QTL, AIP5 QTL displays a maximum -log P value (=5.4) and maps to CI 
between 111.2 to 133.9 Mbp (Table 3.2). As mentioned in Table 3.2, AIP5 QTL also overlaps 
with Collagen-induced arthritis QTL 3 (Cia3), which is one of the two identified loci 
contributing to CIA severity (Cia2 on chromosomes 2 and Cia3 on Chr. 6) (McIndoe et al., 
1999). In our previous study, Cia3 was refined into a 5.6 Mb genomic region on mouse 
chromosome 6 and candidate genes were identified for this locus as well, which will help to 
find the susceptibility gene(s) controlling arthritis development within Cia3 and its 
counterpart regions in rat and human genomes (Yu, Teng et al., 2009). 
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This QTL contains several genes, two of which are close to its peak marker (rs3695725 
at 121.2 Mbp) and appear to be of particular interest as candidate genes. One of these genes is 
C-type lectin domain family 4, member a2 gene (Clec4a2; at 123.1 Mbp), which is 
approximately 1.9 Mbp away from the peak marker of this QTL and the other one is 
peroxisome proliferator-activated receptor gamma (Pparg; at 115.4 Mbp), which is 
approximately 5.8 Mbp far from the peak of this QTL (Table 3.3 & Table 3.4). It is interesting 
to note that these two genes participate in maintaining homeostasis of the immune system as 
well as regulation of cell growth, differentiation and inflammation. Therefore, they could be 
considered as putative candidate genes for AIP5 QTL for further studies. 
4.3.2.1 C-type Lectin Domain Family 4, Member a2 Gene (Clec4a2) 
Clec4a2, also known as dendritic cell immunoreceptor (DCIR), is a C-type lectin 
receptor expressed mainly in dendritic cells (DCs). C-type lectins on dendritic cells can 
influence cellular immune responses by their functions as antigen uptake and signaling 
receptors (Bloem et al., 2014). Studies in DCIR-deficient mice suggest that this receptor is a 
negative regulator of DC expansion and has an important role in maintaining the homeostasis 
of the immune system, which was observed previously in collagen -induced arthritis animal 
model (Fujikado et al., 2008). Accordingly, an obviously exacerbated response to collagen-
induced arthritis was observed in Dcir -/- mice. Recently, DCIR has also been implicated into 
the pathogenesis of human rheumatoid arthritis (Eklöw et al., 2008). Another recent work has 
also suggested that DCIR could be considered as a novel receptor for intravenous 
immunoglobulin (IVIg), which can mediate interaction of innate and adaptive immunity in 
tolerogenic responses (Massoud et al., 2013). 
In current study, AIP5 QTL (confidence interval of 111.2 to 133.9 Mbp) displays the 
highest logarithmic P value (-log P value =5.4) and contains the C type lectin domain family 4 
member a2 (Clec4a2) (at 123.1 Mbp), which is located in a distance of 1.9 Mbp next to the 
peak marker of the QTL (rs3695724) (Table 3.4). Clec4a2 is main susceptibility gene of AIP5 
QTL for several reasons. Firstly, it encodes a receptor protein of dendritic cells that has 
previously been implicated in autoimmune diseases such as Sjogren’s syndrome. Second, the 
association with Sjogren’s syndrome has been observed in AIP patients suggesting that they 
share the same genes that seem to be involved in multiple autoimmune disorders. In addition, 
the role of DCIR in interaction of innate and adaptive immunity in tolerogenic responses 
suggests this gene as promising gene for AIP5 QTL. 
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4.3.2.2 Peroxisome Proliferator Activated Receptor Gamma Gene (Pparg, PPARγ) 
The second candidate gene for AIP5 QTL is Peroxisome proliferator-activated receptor 
gamma (Pparg), which is roughly 5.8 Mbp away from the peak of the QTL (Table 3.3). As a 
member of the nuclear receptor superfamily of ligand-dependent transcription factors, 
Peroxisome proliferator-activated receptor γ (PPARγ) is a key regulator of cell growth, 
differentiation, and inflammation in different tissues. Furthermore, some studies have 
implicated the role of PPARγ in the regulation of critical aspects of development and 
homeostasis, including adipocyte differentiation, glucose metabolism, cell cycle control, and 
monocyte/macrophage differentiation, development and function (Han et al., 2001; Lehmann 
et al., 1995; Spiegelman, 1998; Tontonoz et al., 1998). The ligands of PPARγ, such as 
thiazolidinedione derivatives, have been shown to exert therapeutic effects in experimental 
acute and chronic pancreatitis, as well as to inhibit pancreatic fibrosis by targeting pancreatic 
stellate cells (Hashimoto et al., 2003; Jaster et al., 2005; Shimizu et al., 2002; Van Westerloo 
et al., 2005). 
The confidence interval of AIP, lupus and arthritis QTLs still contain hundreds of genes. 
Therefore, it is feasible that the genes associated with AIP could be different from those 
associated with lupus or arthritis. Nevertheless, it is also possible that the primary 
susceptibility genes for AIP will be shared with other autoimmune diseases. Similar 
observations were made in other genome-wide association studies of common autoimmune 
diseases in humans, e.g. rheumatoid arthritis, diabetes, inflammatory bowel diseases and type 
I diabetes. This could facilitate fine mapping, as mouse and in silico resources are available 
for those diseases. The G4 mice have been extensively phenotyped for signs of other 
autoimmune diseases, i.e. lupus and arthritis, and an analysis of the data to determine 
overlapping and disease-specific QTLs is currently in progress. 
In the next step of this study, we focused on the other three AIP QTLs with -log P 
values of 3.2 ≥ 3.5, which are located on chromosomes 4 (n=2) and 5. Findings are 
summarised in Table 3.6. 
4.3.3 AIP2 QTL  
AIP2 QTL was mapped on chromosome 4 (peak at 18 Mbp; CI: 7.1 to 32.3Mbp) (-log P 
value = 3.2). It can be seen from the data in Table 3.2 that this locus overlaps with two 
previously identified QTLs: Autoimmune aoritis in MRL mice 1 (Aaom1) and  
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Lupus BXSB ×NZW 1 (Lxw1). The association with autoimmune lupus susceptibility traits, a 
linkage to early anti-chromatin antibody production and antigen-specific antibody responses 
are outstanding finding for these two QTLs, which suggests that the common pathway may 
play a role in AIP and other autoimmune diseases.  
4.3.3.1 Autoimmune Aoritis in MRL Mice 1 (Aaom1) 
Aaom1 QTL is associated with autoimmune aoritis in MRL mice and is mapped on 
chromosome 4 at 13.3 cM. The interleukin 11 receptor (IL11R; ~12.7 cM) has been proposed 
as a possible candidate gene for Aaom1, which modulates antigen-specific antibody responses 
in vitro and in vivo (Yin et al., 1992). As MRL/lpr mice develop glomerulonephritis, 
sialoadenitis and arthritis spontaneously, most of the studies focused on this strain as a model 
of human lupus nephritis, rheumatoid arthritis, Sjögren syndrome as well as vasculitis. A 
study of recombinant inbred (RI) strains, MXH/lpr mice strains (MRL/lpr × C3H/lpr mice), 
suggested that systemic vasculitis in MRL/lpr mice is genetically controlled with cumulative 
effects of multiple gene loci with different tissue specificity (Nose et al., 2013). A linkage 
analysis on a population of F2 intercross mice (MRL × C3H ) showed that MRL/MpJ as a 
susceptible parental strain develops spontaneous vasculitis whereas parental strain C3H/HeJ is 
resistant (Yin et al., 1992). It has been also reported that the Aaom1 locus in the MRL strain 
originated from an AKR/J or LG/J strain (Yamada et al., 2003). 
4.3.3.2 Lupus BXSB x NZW 1 (Lxw1) 
Lxw1 (lupus BSXB × NZW 1) QTL maps on mouse chromosome 4 (at 25,683,240-
25,683,429 bp, ~ 6.5 cM) and has a linkage to early anti-chromatin antibody production at 6 
months old mice. To identify QTLs associated with autoimmune lupus susceptibility traits, 
Kono et al performed a genome-wide association study by using (BXSB/Scr × NZW/LacScr) 
F2 female mice. Their result showed that the parental strain NZW/LacScr displays higher 
susceptibility for lupus-associated traits such as glomerulonephritis (GN) and arthritis. In 
addition, the BXSB-inherited chromosome 4 locus designated susceptibility at Lxw1, which 
was linked to early anti-chromatin antibody production (Hamano et al., 2006; Kono et al., 
2003). 
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4.3.4 AIP3 QTL 
The next QTL, AIP3 QTL, was mapped on Chr. 4 with two peaks at 82.4 and 103.6 
Mbp (CI from 81.3 to 120.7 Mbp) (-log P value = 3.3) (Table 3.2 & Table 3.5). In this 
interval, many QTLs have been described affecting other autoimmune diseases like systemic 
lupus erythematosus susceptibility 2 (Sle2), Anti-dsDNA antibody production in NZM 
1(Adaz1), Agnm2, Proteoglycan induced arthritis 27 (Pgia27) and Psoriasis-like skin disease 
severity 1(Psds1). 
4.3.4.1 Systemic Lupus Erythematosus Susceptibility 2 (Sle 2) 
In mice, the Sle2 locus contains several loci that are mapped on chromosome 4, 
influencing the immune system and are associated with B cells hyperactivity (Mohan et al., 
1997; Scatizzi et al., 2012). The Sle2 locus contributes significantly to lupus pathogenesis by 
affecting B cell development (Xu et al., 2004; Xu et al., 2005). It is also linked to 
glomerulonephritis in the NZM2410 mouse. The NZM2410-derived Sle2 lupus susceptibility 
locus induces abnormality in B-cell differentiation and afterward expansion of autoreactive 
B1a cells (Zeumer et al., 2011). It has been shown that Sle2 cannot induce independently any 
autoimmune pathology. However, the synergy between Sle2 and lpr leads to accelerated 
lymphadenopathy that largely target T cells (Xu et al., 2011). In addition, Sle 1, 2, 3 mice 
have been suggested as useful tools for studying the role of IFN in the pathogenesis of lupus 
(Sriram et al., 2012). 
4.3.4.2 Anti-dsDNA Antibody Production in NZM 1(Adaz1) 
Anti-dsDNA antibody production in NZM 1 (Adaz1) locus was mapped on chromosome 
4 in NZM2328 mice which was suggestively linked to plasma levels of IgG anti-dsDNA 
autoantibodies (Waters et al., 2001). This locus stretches out in the region similar to Sle2 in 
NZM2410. Adaz1, however, is derived from NZB, whereas Sle2 is derived from NZW 
(Bagavant et al., 2004). 
4.3.4.3 Autoimmune Glomerulonephritis in MRL 2 (Agnm2) 
Agnm2 is a QTL associated with autoimmune glomerulonephritis in MRL2 and mapped 
on chromosome 2 at confidence interval ~ 45.76 cM (at 100423186-124575207 bp). 
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Glomerulonephritis (GN) is one of the most important diseases in SLE. Therefore, Miyazaki 
et al. performed a QTL mapping to identify genes associated with susceptibility to GN using 
(MRL/lpr × C3H/lpr) F2 mice. Three susceptibility loci on two chromosomes are designated 
loci of autoimmune GN in MRL mice: Agnm1 at 19.8–24.5 cM, and Agnm2 at 49.6–57.6 cM 
on chromosome 4, and Agnm3 at 54.0–65.0 cM on chromosome 5. It has also been suggested 
that Agnm1 and Agnm2 could share two susceptibility loci to systemic vasculitis. In addition, 
recessive or semi-dominant GN susceptibility genes might exist in the MRL strain, a 
hypothesis that is based on the data of relative decrease in the incidence in the F1 or F2 mice 
(Miyazaki et al., 2005). 
4.3.4.4 Proteoglycan Induced Arthritis 27 (Pgia27) 
Studies in animal models of inflammatory arthritis have identified more than 20 loci that 
are either specific to this animal model or shared with other models or with RA in humans 
(Adarichev, Valdez et al., 2003; Barton et al., 2001; Besenyei et al., 2012). In various species, 
different chromosome regions are linked with some traits of arthritis (i.e. the severity, onset, 
susceptibility, the production of antibodies and cytokines) and are overlapping with several 
autoimmune diseases, suggesting that they share common genetic components (Bauer et al., 
2004; Glant et al., 2004; Kamogawa et al., 2002). Studying the effect of sex on various traits 
in murine models of RA demonstrated differences in several features of arthritis between male 
and female (Adarichev, Nesterovitch et al., 2003; Tengstrand et al., 2004; Weyand et al., 
1998). However, Pgia27, which is located on Chr.4 at position 35–45cM, is prominent in 
male and is associated with the severity of disease. In a genome-wide association study that 
was carried out by Adarichev et al., all QTLs revealed different LOD scores or variation of the 
peak position regarding sexes. Interestingly, few QTLs were entirely sex-associated with both 
binary and onset QTLs higher in females than in males. In contrast, severity QTLs were more 
prominent in males than in females (Adarichev, Nesterovitch et al., 2003). It has been shown 
that in a murine animal model of RA, proteoglycan-induced arthritis (PGIA), severe arthritis is 
dependent on the production of IFN-γ (Doodes et al., 2010; Moudgil et al., 2011). Studying 
the role of IL17 in PGIA showed that IL17is not completely required for autoimmune arthritis 
and the production of other pro-inflammatory mediators is compensating for the loss of IL17 
in PGIA (Doodes et al., 2008). 
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4.3.4.5 Psoriasis-like Skin Disease Severity 1(Psds1) 
Psoriasis-like skin disease severity 1 (Psds1) locus is mapped to 42.5 cM on mouse 
chromosome 4 and shows significant linkage to skin disease severity. It has also a weak 
linkage to defective CD4+ dendritic cell development. Two potential candidate genes have 
been found in this interval:interferon alpha/ interferon beta (Ifna/Ifnb) gene cluster (~ 42.6 
cM) and Jun (~ 44.6 cM). The c-Jun proto-oncogene is a member of the Jun family of 
transcriptional regulatory proteins and may play a role in regulating the genomic response to 
growth factors. In the linkage analysis, which was performed to identify genetic modifiers of 
psoriasis-like skin disease, parental strain C57BL displays accelerated psoriasis-like skin 
disease due to increased Ifna/Ifnb responses. In contrast, parental strain BALB does not 
develop skin disease. Another locus is mapped to an interval between D4Mit204 (~ 61.9 cM) 
and D4Mit54 (~ 66 cM) and was named Psds2 (psoriasis-like skin disease severity 2).It shows 
significant linkage to defective CD4+ dendritic cell development (Arakura et al., 2007). 
4.3.5 AIP4 QTL 
AIP4 QTL was mapped on Chr. 5 (CI 74.8 to 96.6 Mbp) (-log P value = 3.5) (Table 3.2 
& Table 3.5) and displayed an overlapping with Cdcs10 QTL, a QTL that is associated with 
colitis in interleukin-10-deficient (Il10 −/−) mice (Mähler et al., 2002). Experimental 
inflammatory bowel disease (IBD) in this mice can occur spontaneously or is induced by 
chemicals, cell transfer, pathogens, or genetic mutation (de Buhr et al., 2006; Hillhouse et al., 
2011). 
4.3.5.1 Cytokine Deficiency Colitis Susceptibility 10 (Cdcs10) 
Genome screens for quantitative trait loci (QTLs) regulating colitis susceptibility 
identified Cdcs10 as one of main effective QTLs on chromosomes 5 at position 47.29 cM in 
interleukin-10-deficient (Il10 −/−) mice (Mähler et al., 2002). Using the IL10-deficient mouse 
model, the first colitogenic QTL was identified and termed cytokine deficiency-induced colitis 
susceptibility 1 (Cdcs1) (Farmer et al., 2001). This quantitative trait locus and it`s subintervals 
were replicated in several studies, which is based on dysregulation of innate or adaptive 
immunity or pathogen control in animal models (Bleich et al., 2010; Buettner & Bleich, 
2013). Moreover, the associations between 10 QTLs (Cdcs1–10, cytokine deficiency-induced 
colitis susceptibility 1–10) and colitis susceptibility in segregating populations of Il10 −/− mice 
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have been reported (Farmer et al., 2001; Mähler et al., 2002). The severity of colitis in these 
mice depends on their genetic background (i.e. mice with C3H/HeJBir background develop 
more severe colitis than animals with C57BL/6J background) (Ermann et al., 2011; Mähler et 
al., 2002). 
Taken together, in this new four-ways autoimmune-prone advanced intercross line 
(AIL) five new loci linked to AIP were identified. The strongest linkage was found for a 
region on mouse chromosome 6, which has been implicated in our previous study of collagen-
induced arthritis (Yu, Teng et al., 2009). The other strong linkages were observed for loci on 
chromosomes 2, 4 and 5 that have formerly been observes in susceptibility to experimental 
allergic encephalomyelitis, systemic lupus erythematosus and CIA. These five AIP-linked 
QTLs colocalized with QTLs identified in mouse models for other autoimmune diseases (i.e. 
RA, EAE, SLE), suggesting that, at least in part, common genetic pathways may play roles in 
AIP and the other autoimmune diseases. Although the final targets for the autoimmune 
response in these diseases are diverse, the same gene products could complete the mechanism 
to break down tolerance to self-components. Furthermore, our results provide additional 
support for the hypothesis that QTLs controlling other autoimmune diseases might affect AIP 
development as well. 
4.4 Pathogenesis of AIP in G4 Mice 
The initial events triggering AIP remain unknown. Some hypotheses proposed that 
primarily infection of pancreatic cells by viral or infectious agent may initiate an immune-
mediated processe, which is supported by several observations (Filippi et al., 2009; Filippi & 
von Herrath, 2008; Oldstone et al., 1991; Yanagisawa et al., 2011). The autoimmune 
mechanism of AIP is based on molecular mimicry between ubiquitin-protein ligase E3 
component n-recognin 2 (UBR2) and an amino acid sequence of the plasminogen-binding 
protein (PBP) of Helicobacter pylori, or a homology between Helicobacter pylori virulence 
factor cag A (cytotoxin-associated gene A) and the carbonic anhydrase II (Frulloni et al., 
2009; Guarneri et al., 2005). Another important finding in this context was the mechanism 
which was suggested for the virus-induced AIP mouse model (Watanabe et al., 2003). 
Cumulatively, these features provide further evidence that AIP is an immune-mediated 
inflammatory process. 
However, the pathogenesis of AIP remains to be explored further. Recently, 
considerable attention has been directed to T helper cell-released pro-inflammatory cytokines 
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and their role (regulation and responses) in the pathogenesis of AIP. Despite of its simplicity, 
the concept of Th1/Th2 inequity has been used to interpret the pathogenesis of organ-specific 
autoimmune diseases (Adorini et al., 2002). It is believed that T helper imbalance, Th1 against 
Th2, is associated with the initiation of AIP (Zen & Nakanuma, 2011). Moreover, elevated 
Th1 responses in both pancreatic and extra-pancreatic lesions have been reported in AIP 
patients (Okazaki et al., 2000; Zen et al., 2007). Furthermore, a Th1 immune response has 
been considered to be predominant in type 1 AIP (Okazaki et al., 2000), and T helper 1 cell-
released pro-inflammatory cytokines have been implicated in the pathogenesis of autoimmune 
pancreatitis. On the other hand, it has been demonstrated that the number of regulatory T-cells 
(Tregs) are increased in tissue-resident lymphocyte populations and whole blood of patients 
with type 1 AIP (Zen et al., 2007). In contrast to earlier findings, however, recent studies 
provided data in support of a Th2 predominant immune response in IgG4-RD (Okazaki et al., 
2013). 
Differentiation of murine CD4+ T cells into Th1 or Th2 or Th17 subsets is dependent 
upon many different factors. For instance, IFN-γ and IL12 initiate the differentiation of Th1 
cells, whereas IL4 triggers the differentiation of Th2 cells. There is considerable evidence that 
show the importance of IFN-γ	  and IL17 in the development and progression of inflammatory 
and autoimmune diseases (AID) in both humans and mice. It has been also suggested that an 
autoimmune mechanism, relying on Th1 immune response, might be involved in AIP. IFN-γ 
is a pro-inflammatory cytokine released by Th1 cell and plays a role in the pathogenesis of 
autoimmune pancreatitis. It has been shown that IFN-γ treated AIP-prone MRL/Mp mice 
developed more severe AIP (Fitzner et al., 2009). 
Based on all these data, it is reasonable to expect that a QTL controlling T-helper cell 
differentiation may also play a role in immune-mediated diseases, especially in AIP. 
Therefore, the results of our analysis that show the overlap of several QTLs controlling 
immunological traits with AIP QTLs may be important in understanding the role of T helper 
cells in the pathogenesis of AIP. 
4.4.1 AIP1 QTL and Immune Cell Phenotypes 
To examine whether AIP QTLs overlap with QTLs controlling Tregs cell development, 
we examined the association between AIP QTLs and CD4+FoxP3+ and CD8+FoxP3+ 
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phenotypes. This revealed the potential pathway in which the susceptibility genes inside these 
QTLs might be involved. 
Figure 3.5 and Table 3.9 provide the largest data set from AIP1 QTL. The most 
interesting finding was a complete overlapping between all 12 markers (SNPs) associated with 
AIP in this region and CD4+ FoxP3+ and CD8+ FoxP3+ phenotypes with high logarithmic P 
values varying from 3.2 to 7.11. The peak region of AIP1 QTL with the highest -log P value 
(=7.11) for CD4+ FoxP3+ phenotype overlaps with the previously identified QTLs associated 
with arthritis (Cia2 and Cia4, two QTLs that controlling severity and onset of the disease) 
(Bauer et al., 2004) and the murine models of multiple sclerosis (Eae21and Eae33) (Butterfield 
et al., 2000; Peláez et al., 2005). In contrast, QTLs for both these phenotypes do not overlap 
with other AIP QTLs on chromosomes 4, 5 and 6. These results are consistent with those of 
other studies, and suggest that the susceptibility gene(s) inside these QTLs are affecting the 
AID clinical phenotypes (Bailey et al., 2007; Yu, Teng et al., 2009). This also supports a 
possible role for Tregs in the initiation of the disease. Moreover, the findings of the current 
study correspond to observations made by Koyabu et al. who reported a correlation between 
an early development of pancreatitis with an abundant infiltration of Foxp3-positive cells in 
MRL/Mp mice treated with poly I:C. This is highlighting a possibility that Tregs may be 
involved in the development of pancreatitis in these mice (Koyabu et al., 2013). 
Interestingly, a strong linkage was observed for this locus (rs6378343, 6:63823084bp, 
 ~ 32.20cM) with CD8+ FoxP3+ phenotype (-log P value = 4.9) (Figure 3.5 B). This locus 
overlaps with Cia6, collagen-induced arthritis QTL 6 (Popovic et al., 2008), a QTL that shows 
an association to the region encoding the Tcr beta chain (H.-T. Yang et al., 1999). Four genes 
were mapped in this region between 30.81 and 32.14 cM. These genes are involved in a 
co-stimulatory pathway that plays a key role in regulating the inflammatory process 
interaction between APC and T cells. These genes are CD8 antigen alpha chain (Cd8a), CD8 
antigen beta chain 1 (Cd8b1), interleukin 23 receptor (Il23r) and interleukin 12 receptor, beta 
2 subunit (Il12rb2). 
Interleukin 23 receptor (Il23r) encodes a protein that serves as a subunit of the receptor 
for IL23A/IL23 and couples with the receptor molecule IL12R beta1. Both of these receptors 
are required for IL23A signaling. Fundamentally, this receptor protein binds to Janus kinase 2 
(JAK2), and the transcription activator STAT3 (Parham et al., 2002) that is required for the 
differentiation of T helper17 cells (Bettelli et al., 2007; X. O. Yang et al., 2007) that have been 
implicated in a variety of autoimmune diseases. Moreover, it has been reported that IL12 
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receptor beta 2 subunit plays a role the inflammatory response and host defense (Rodgers & 
Miller, 2012). 
Interestingly, one of the most strongly associated loci with Foxp3+ phenotypes was 
mapped on Chr. 7 (rs3699086, ~ 52.28cM) with maximum -log P value (=7.38) (Figure 3.5). 
This locus overlaps with “IL4 producing potential QTL (Lat)”, which is essential to T cell 
activation (W. Zhang et al., 1998). Putative candidate genes found in the region of the peak 
marker may have an influence on the inflammatory process of an autoimmune disease. These 
genes are IL4 receptor alpha gene (Il4ra), interleukin 18 binding protein (Il18bp) and 
immunoglobulin super family member 6 (Igsf6), which map to the inflammatory bowel 
disease 1 locus (Bates et al., 2000). 
Il4ra encodes a protein, alpha chain of the IL4 receptor, which can bind IL4 to promote 
differentiation of Th2 cells (Sharma et al., 2013). In 2006, a single significant QTL on 
chromosome 7 has been identified, controlling the potential production of IL4 in SLE model 
of NZB, BXSB and related mouse strains. Il4Rα gene, as a putative gene in this region, seems 
to be interesting due to identical sequence between NZB and BXSB strains, and eight amino 
acid differences between NZB and the NZW strains. However, a limited potential of IL4 
production has been detected in both SLE-prone NZB and BXSB mice, whereas disease-free 
NZW mice had a high potential and (NZB × NZW) F1 and (NZW × BXSB) F1 are in between 
both of them. Therefore, it is logical to propose that the NZW-type polymorphism controls a 
high potential and that the NZB/BXSB-type polymorphism controls a low potential for IL4 
production by T cells. Thus, the low IL4-producing phenotype appears to predispose to SLE 
in BXSB, but not in NZB-related strains, suggesting that the role of IL4 in the pathogenesis 
may differ between certain subsets of SLE, even if they show similar disease phenotypes 
(Shiroiwa et al., 2007). 
Interleukin 18 binding protein (Il18bp) a novel modulator of the Th1 cytokine response, 
encodes a protein, which is an inhibitor of the pro-inflammatory cytokine IL18 (Novick et al., 
1999). This protein is regularly expressed and secreted in mononuclear cells, binds to IL18, 
prevents the binding of IL18 to its receptor, and thus inhibits IL18-induced IFN-gamma 
production. 
The other locus maps on Chr.9 (rs3700596, ~ 43.49 cM) and shows a significant 
association for two following phenotypes: CD4+ FoxP3+ (-log P value = 8.975),  
CD8+ FoxP3+ (-log P value = 5.63). This interval contains T lymphocyte fraction gene (Tlf) 
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(~ 52.24 cM), which is associated with autoimmune diabetes and appears to be a putative gene 
for this loci (Pearce, 1998). 
It is interesting to note that all 12 SNPs in the region controlling AIP susceptibility 
(AIP1 QTL) showed a strong linkage to CD8+ CD69+ phenotype with logarithmic P value of 
3.31 to 6.46 (Table 3.9 and Figure 3.5). CD69 is a marker of early T cell activation and 
expressed on activated lymphocytes. Its selective expression in inflammatory infiltrates 
suggests that it plays a role in the pathogenesis of inflammatory diseases (Hasegawa et al., 
2013). Respectively, the association between the leukocyte activation antigen CD69 and T cell 
differentiation towards Th1 or Th17 has been reported in several studies (Dorfman & 
Shahsafaei, 2002; Martin et al., 2010). Taken together, our observation supports the 
conclusion that genetic factors contribute significantly to an inflammatory process in G4 mice. 
Particularly, this part of our results confirms the role of the early activation receptor CD69 to 
modulate T-cell differentiation as a part of the immune inflammatory response in this 
progeny. To investigate the immunological pathways more thoroughly, the influence of AIP 
QTLs on the T helper cells differentiation towards Th1, Th2 and Th17 and a possible linkage 
between AIP QTLs and T helper subtype markers were verified. 
4.4.2 Effect of AIP QTLs on Th1/Th2-type Cellular Immune Response 
It has been shown that autoimmune-related pancreatitis is associated with autoantibodies 
and a Th1/Th2-type cellular immune response (Okazaki et al., 2000). Qu and coworkers 
demonstrated that TNF-α levels are increased in the serum of patients with pancreatitis as well 
as in animal models of pancreatitis (Qu et al., 2002). To determine the effects of IFN-γ, 
Fitzner et al. applied the cytokine directly to AIP-prone MRL/Mp mice. According to their 
results, IFN-γ accelerates and aggravates AIP in MRL/Mp mice (Fitzner et al., 2009). 
Therefore, to examine the effects of Th1/Th2 cellular immune response in AIP, the overlap 
between AIP QTLs and CD4+ IFN-γ+ and CD4+ IL4+ phenotypes as covariates was analysed, 
thus providing information about possible mechanisms underlying AIP QTLs function. 
To identify quantitative trait loci controlling Th1/Th2 phenotypes in G4 mice, we 
examined five AIP QTLs by investigating the association between them and the 
immunological phenotypes. AIP2 QTL was strongly linked to CD4+ IFN-γ+ (Th1) phenotype 
in its peak markers, as indicated by one peak on Chr. 4 at 9.39 cM (-log P value = 9.012) and 
another peak at 8.34 cM (-log P value = 5.132) (Figure 3.6). Previous studies also identified 
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Lxw1 and Aaom1, and Nbwa2 (NZB and NZW autoimmunity 2 QTL) QTLs in this region that 
control clinical traits in arthritis and lupus animal models. This QTL contains the interferon 
kappa gene (Ifn-κ), which encodes a protein that is expressed at low levels in peritoneal 
macrophages. Its expression is up-regulated by dsRNA and IFN-γ. IFN-κ belongs to a recently 
identified subclass of type I IFNs (LaFleur et al., 2001). The murine type I interferon (Ifn-
kappa) is expressed in the pancreatic islets and induces diabetes in mice (Vassileva et al., 
2003). Overexpression of murine Ifn-κ in the β cells of the pancreas of transgenic mice 
induces development of diabetes that is histologically characterized by inflammatory 
infiltrates with corresponding destruction of β cells (Vassileva et al., 2003). 
Interestingly, the same QTL, AIP2 QTL, displays association with CD4+ IL17+ (Th17) 
phenotype (Figure 3.8) for both peak markers (mCV22939387 at position 8.341cM (-log P 
value = 4.609) and rs6287606 at position 9.388 cM (-log P value = 4.987). This finding seems 
to be consistent with previous reports which suggested that T helper inequity is associated 
with the initiation of AIP (Zen & Nakanuma, 2011). 
4.4.3 T helper 17 (Th17) and AIP 
It is interesting to address whether these newly identified AIP QTLs controlling 
immunological traits also affect the AIP development. The role of T helper 17 (Th17) and 
regulatory T cells (Tregs) in human organ transplantation and autoimmune diseases has been 
studied (Afzali et al., 2007) in detail. It has also been demonstrated that Th17 cells 
significantly contribute to the pathology of autoimmune diseases (Afzali et al., 2007; Kim et 
al., 2013). For example, in their study, Kim et al. detected elevated levels of Th17 cells, which 
are associated with disease activity in patients with rheumatoid arthritis (Kim et al., 2013). 
In order to verify the linkage between AIP QTLs and immunological traits, and identify 
possible mechanisms underlying QTL function, a genotype/phenotype overlap analysis was 
performed in this study. The results indicate that in AIP5 QTL region, out of 16 SNPs with a 
high logarithmic P values for AIP, five SNPs displayed overlap with CD4+ IL17+ phenotype. 
In AIP2 QTL region, only 2 SNPs out of 5 SNPs (linked to AIP) showed overlap with this 
phenotype (Figure 3.8 & Table 3.10). 
The most important findings in these regions are listed in Table 3.11. Interestingly, these 
QTLs (AIP2 and AIP5 QTLs) also overlap with previously identified autoimmunity QTLs, i.e. 
Cypr5; cytokine production 5 QTL, Cia3 and inflammatory bowel disease QTL 2 (Ibdq2). 
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Some genes in this interval, lymphotoxin B receptor gene (Ltbr); interleukin 17 receptor A 
gene (Il17ra), Cd4 antigen and Cd69 antigen, seem to serve as possible candidate genes for 
this phenotype. 
Probably, a part of these findings corroborates the ideas of Seleznik et al. who detected 
high messenger RNA levels of lymphotoxin (LT) α and β in pancreatic tissues from patients 
with AIP, compared with controls. The authors suggested that overexpression of LT αβ in 
acinar cells of the mouse leads to an AIP-like illness (Seleznik et al., 2012). As mentioned 
above, AIP5 QTL contains lymphotoxin B receptor gene (Ltbr), which encodes a protein that 
is a member of tumor necrosis factor family (TNF). Pancreatic acinar cells produce, release, 
and respond to TNFα, a member of the TNF family, which regulates apoptosis in isolated 
pancreatic acini also in  experimental pancreatitis (Bhatia et al., 2000; Gukovskaya et al., 
1997). 
Definitely, the most interesting finding in this analysis was a single strong linkage to 
CD4+ IL17+ phenotype for region (quantitative trait locus) that was identified on Chr.18 with 
the highest -log P value ˃9 (Figure 3.8) in its peak for two SNPs. The first peak marker 
(rs3658163 at 68661314 bp) for this locus (~34.776 cM) displayed a strong linkage  
(-log P value = 9.614) (Figure 3.8). Interestingly, this locus showed colocalization with T 
helper cell response QTL (Thcr) (at position 44997537-6864706 bp), which controls NKT cell 
homeostasis and T helper cell differentiation in mice (Zhang et al., 2003; Zhang et al., 2006). 
Several recent genetic studies showed that Thcr QTL also overlaps with previously identified 
murine systemic lupus erythematosus susceptibility loci (Vyse & Kotzin, 1998) and loci that 
are associated with murine experimental autoimmune encephalomyelitis (EAE) (Baker et al., 
1995). 
The other peak of this QTL (-log P value = 9.337) mapped to the region (rs3691542, at 
66474868 bp, ~ cM 33.86) (Figure 3.8) involves interleukin 17B gene (Il17b) (Chr. 18: 
61687935-61692537 bp). The protein encoded by this gene is a T cell-derived cytokine that 
shares sequence similarity with IL17 (Shi et al., 2000). 
In addition, linkage studies of autoimmune diseases such as insulin-dependent diabetes 
mellitus, rheumatoid arthritis, systemic lupus erythematosus have identified susceptibility loci 
on human chromosome 18 in the region, which are homologous with the same region on 
mouse chromosome 18 (Cornélis et al., 1998; Merriman et al., 1998; Shai et al., 1999). 
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All together, this study has identified several QTLs associated with AIP clinical 
phenotypes, thus illustrating the underlying complexity of autoimmune diseases. Since AIP is 
a complex disease influenced by many factors, it is reasonable to speculate that genes 
controlling other immune phenotypes might affect AIP development. On the other hand, these 
newly identified QTLs co-localize with other known autoimmunity QTLs, suggesting 
common genetic components. Simultaneously, these evidences are providing essential 
information on the pathogenesis of AIP. Our results confirm the findings of a great deal of 
previous work performed in this field. Further research can be performed to identify the 
disease-responsible genes. 
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5 Conclusions 
Recent advances in molecular and genetic methodologies should further confirm our 
understanding of AIP as a complex disease. The use of experimental animal models of AIP 
initiated a considerable progress towards understanding the pathophysiology of the disease. 
This study identified the main genetic loci (QTLs) controlling AIP. As in other autoimmune 
diseases, we expected AIP to be polygenic with a strong contribution of a small number of 
genes and probably weak contribution of large numbers of additional genes. 
This is the first time such a study has been performed. Further intercrossing currently 
pursues fine mapping of the identified QTLs. Taken together, these insights into the 
pathogenesis of AIP will confidently lead to the identification of novel diagnostic and 
therapeutic targets. 
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6 Summary 
Autoimmune pancreatitis (AIP) is a rare form of chronic pancreatitis that is 
characterised by infiltrates of inflammatory cells in the pancreas and, in severe cases, 
destruction of acinar tissue. T cell-mediated autoimmunity plays a predominant role in the 
pathogenesis of the disease, although the high prevalence of various autoantibodies indicates a 
humoral component of the autoimmune reaction as well. Despite being rare, AIP is clinically 
important since the disease is a differential diagnosis of pancreatic cancer and could be treated 
with steroids efficiently. 
Using a mouse model of AIP, we have identified susceptible regions of the genome 
(quantitative trait loci; QTLs) which provide the first evidence for a genetic component of the 
disease. To identify quantitative trait loci of AIP, we established an advanced intercross line 
originating from three inbred mouse strains: MRL/MpJ (spontaneous development of AIP), 
BXD2 (susceptible to collagen-induced arthritis), NZM (model of Lupus erythematodes) and 
wild derived strain Cast (healthy controls). 
This approach promises to identify both general autoimmune disease-associated genetic 
loci and further for AIP. Therefore, the fourth generation of outbred intercross mice was 
characterized phenotypically by scoring histopathological changes of the pancreas and 
genotyped with SNP arrays (Illumina, USA). 
Five QTLs, regulating the severity of AIP were identified. Two of them mapped to 
chromosome 4 while one was mapped to chromosomes 2, 5 and 6 each. The QTL on 
chromosome 6 displays the highest logarithmic P value (-log P = 5.4) and contains the C type 
lectin domain family 4 member a2 near to peak SNP (rs3695724). The gene encodes a 
receptor protein of dendritic cells, which has previously been implicated in other autoimmune 
diseases such as Sjogren’s syndrome. AIP candidate genes of other QTLs include 
heterogeneous nuclear ribonucleoprotein A3, nuclear factor (erythroid derived 2)-like2, 
Sjogren syndrome antigen B, and Ubiquitin protein ligase E3 component n-recognin 3 
(UBR3). 
Moreover, we found AIP QTLs 1 and 5 overlapping with genetic loci controlling other 
immunological phenotypes in the same cross. The strongest evidence was suggested for the 
relative abundances of double positivity for CD4+ FoxP3+, CD8+ FoxP3+, CD8+ CD69+ and 
CD4+ IL17+ in mice splenocytes. The data suggest that QTL controlling Treg development or 
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T-helper cell differentiation could also modulate immune-mediated diseases, especially AIP, 
and that the susceptibility genes within these QTLs affect the autoimmune diseases clinical 
phenotypes. 
A single strong linkage to CD4+ IL17+ phenotype (-log P ˃9, peak SNPs = rs3691542 & 
rs3658163) and a quantitative trait locus were identified on chromosome 18 in a region 
homologous to human chromosome 18. This locus with the highest logarithmic P values 
colocalizes with the T helper cell response (Thcr) QTL, which controls NKT cell homeostasis 
and T helper cell differentiation in mice. The locus contains the interleukin 17B gene (Il17b) 
which is a T cell-derived cytokine that shares sequence similarity with IL17. 
This study identified the main loci controlling AIP in a mouse model of the disease. As 
in other autoimmune disorders, we could confirm the expectation of AIP to be polygenic with 
a strong contribution of a small number of genes (constrained by five dominant QTLs) and 
weak contribution of large numbers of additional genes. To the best of our knowledge, this is 
the first time such a study has been performed. The further fine mapping of the QTLs, in order 
to find candidate gene could be accessed using intercrossing more generation, which is now 
G16. These insights into the pathogenesis of AIP will hopefully lead to the identification of 
novel diagnostic and therapeutic targets. 
 
 Zusammenfassung  
77 
 
 
7 Zusammenfassung 
Die autoimmune Pankreatitis (AIP) ist eine seltene Form der chronischen Pankreatitis, 
die durch Infiltration von Entzündungszellen in die Bauchspeicheldrüse sowie in schweren 
Fällen auch durch die Zerstörung von Azinusgewebe gekennzeichnet ist. Die T-Zell-
vermittelte Autoimmunität spielt eine bedeutende Rolle in der Pathogenese der Erkrankung, 
obwohl die hohe Prävalenz von verschiedenen Autoantikörpern auch eine humorale 
Komponente der Autoimmunreaktion belegt. Ungeachtet ihres seltenen Vorkommens ist die 
AIP klinisch wichtig, da sie eine Differentialdiagnose gegenüber dem 
Bauchspeicheldrüsenkrebs darstellt und effizient mit Steroiden behandelt werden kann. 
Durch die Verwendung eines Maus-Modells für die AIP konnten Regionen des Genoms 
(Quantitative Trait Loci, QTLs), die mit der Anfälligkeit assoziiert sind, identifiziert werden 
und somit die ersten Beweise für eine genetische Komponente der Erkrankung aufgezeigt 
werden. Um QTLs für die AIP identifizieren zu können, wurde eine Vier-Linien-Kreuzung, 
genannt „advanced intercross line“ aus vier Mausstämmen generiert: MRL/MpJ (entwickeln 
eine spontane AIP), BXD2 (sind anfällig für die Kollagen-induzierte Arthritis), NZM (dienen 
als Modell für den Lupus erythematodes) und Cast (gesunde Kontrollen). 
Dieser Ansatz verspricht die Identifizierung von Genombereichen, die sowohl allgemein 
mit Autoimmunerkrankungen als auch speziell mit der AIP assoziiert sind. Daher wurden die 
Mäuse aus der vierten Generation dieser Aufzucht-Kreuzung durch Bewertung der 
histopathologischen Veränderungen der Bauchspeicheldrüse phänotypisiert und mit einem 
SNP-Array (Illumina, USA) genotypisiert. 
Fünf QTLs, die mit der Schwere der AIP korrelieren, wurden identifiziert. Zwei QTLs 
konnten auf Chromosom 4 lokalisiert werden, während die anderen sich auf den 
Chromosomen 2, 5 und 6 befinden. Der QTL auf Chromosom 6 wies den niedrigsten P-Wert 
(-log P = 5.4) auf und lokalisiert in der Spitzenregion (rs3695724) eine C-Typ Lektin-Domäne 
(Clec4a2). Diese kodiert für ein Rezeptorprotein dendritischer Zellen und wurde kürzlich mit 
anderen Autoimmunerkrankungen wie dem Sjögren-Syndrom in Verbindung gebracht. 
Weitere AIP- Kandidatengene der anderen QTLs sind das „heterogenous nuclear 
ribonucleoprotein A3 (Hnrnpa3)“, „nuclear factor (erythroid derived 2)-like2“, „Sjogren 
syndrome antigen B“, und „Ubiquitin protein ligase E3 component n-recognin 3 (UBR3)“. 
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Wir konnten zeigen, dass die identifizierten AIP QTLs 1 und 5 mit Genombereichen 
überlappen, welche mit immunologischen Phänotypen assoziiert sind. Die stärkste Evidenz 
konnten wir zur relativen Häufigkeit doppeltpositiver CD4+FoxP3+, CD8+FoxP3+, 
CD8+CD69+ und CD4+IL17+ Zellen aufzeigen. Diese Daten legen nahe, dass 
Immunerkrankungen, insbesondere die AIP, durch die QTL-gesteuerte Entwicklung von Treg-
Zellen bzw. die T-Helferzell-Differenzierung moduliert werden können, und dass die 
Anfälligkeitsgene innerhalb dieser QTLs die klinische Ausprägung der 
Autoimmunkrankheiten beeinflussen können. 
Eine starke Assoziation zum IL17+ CD4+ Phänotyp (-log P ˃9, Spitzen SNPs = 
rs3691542 & rs3658163) und ein QTL wurden außerdem auf Chromosom 18 identifiziert, in 
einer Region, die homolog zum humanen Chromosom 18 ist. Dieser Genort mit dem höchsten 
log(P)-Wert von ˃ 9 ist kolokalisiert mit einem QTL für die T-Helferzellantwort (Thcr), der 
die NKT-Zell-Homöostase und die T-Helfer Zelldifferenzierung in Mäusen steuert. Dieser 
Lokus beinhaltet das Interleukin 17B-Gen (Il17b). Das entsprechende Protein ist ein T-Zell-
Zytokin, welches Sequenzhomologien mit IL17 aufweist. 
In dieser Studie wurden die wichtigsten Genombereiche identifiziert, welche im 
Mausmodell die AIP regulieren. Wie bei anderen Autoimmunerkrankungen konnten wir die 
Erwartung bestätigen, dass auch die AIP eine polygene Erkrankung ist, bei der eine kleine 
Anzahl von Genen (begrenzt durch fünf QTLs) mit großem Einfluss, sowie eine große Anzahl 
zusätzlicher Gene mit schwächerem Einfluss von Bedeutung sind. Nach unserem 
Kenntnisstand ist dies die erste Studie auf diesem Gebiet. Die Feinkartierung der 
identifizierten QTLs wird durch weitere Kreuzung fortgesetzt - die 16. Generation wurde 
gerade erreicht. Diese Einblicke in die Pathogenese der AIP werden hoffentlich zur 
Identifizierung neuer diagnostischer und therapeutischer Ziele führen. 
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9 Appendix 
Appendix 1. Immunological cell markers and mouse CD markers for immunophenotyping  
Markers Distribution 
Basic T cells 
CD3 T cells 
CD4 Tcells, Dcs, NK cells, Stem Cell/Precursor  not 
Macrophage/Monocyte (Thymocyte subset, T subset, DCs)  
CD8 T cells, DCs(CD8a+) (Thymocyte subset, T subset, DC subset, not 
fresh NK)*  
CD45R (B220, PTPRCa ) T Cells, B Cells, DCs, NK Cell, Stem Cell/Precursor, 
Macrophage/Monocyte (B, NK progenitors, LAK, T act) * 
CD4 or CD8 Memory/ Activated  
CD44 TCell, B Cell, Macrophage/Monocyte, Granulocyte, Erythrocyte, 
Endothelial Cell, Epithelial Cell (broad, memory T, not platelets, or 
hepatocytes) *  
CD62L T-Cell, B Cell, NK Cell, Macrophage/Monocyte, Granulocyte (B, 
T, monocyte, granulocyte, NK, thymocytes) *. Central memory T-
lymphocytes, which have encountered antigen, express L-selectin to 
localize in secondary lymphoid organs 
CD69 Very Early Activation Antigen, Nk cells, (T act, B act, NKact , 
granlocyteact, thymocytes, platelets ) * 
B cell Activation  
CD19 B Cell ,DCs, Stem Cell/Precursor (B, FDC, good B lineage 
marker,not plasma cells) * 
CD69 Nk cells, (T act, B act, NKact , granact, thymocytes, platelets ) 
CD86 T Cell, B Cell ,Dendritic Cell, Macrophage/Monocyte, Endothelial 
Cell (monocyte, B act, NKact, DCs)* 
MHC Class II APC, DCs, B cells 
Dendritic Cell (DCs)  
CD11c T Cell, DCs, NK Cell ,Stem Cell/Precursor, Macrophage/Monocyte, 
Granulocyte( DC, myeloid,NK, T subset)  
PDCA-1 Plasmacytoid dendritic cells (PDC) 
CD86 T Cell, B Cell ,DCs, Macrophage/Monocyte , Endothelial Cell 
(monocyte, B act, NKact, DCs)* 
Regulatory T cells (Tregs) 
FoxP3 * MHC class II restricted Foxp3-expressing CD4+CD25+ Tregs or 
MHC class I restricted CD8+ Foxp3-expressing Tregs  
T helpers   
IFN gamma The signature cytokines of T helper1 cells, which was shown to 
assist Th1 development  
IL4 T helper 2, activated CD4+cells, memory CD4+cells 
IL17  T helper 17 cells 
PTPRC; Protein tyrosine phosphatase receptor type C, DCs; Dendritic Cells, NK Cell; Natural killer 
cells, APC; antigen presenting cell, B act (also Tact. & NKact); activated B, T or NK cells, LAC; 
lymphokine-activated killer cell. 
BD Bioscience Mouse CD Marker Poster and Handbook: 
(http://www.ebioscience.com/resources/mouse-cdchart.htm) 
(http://www.bdbiosciences.com/documents/BD_Reagents_CDMarkerMouse_Poster.pdf), 
(http://www.bdbiosciences.com/documents/cd_marker_handbook.pdf), 
*eBioscience Mouse CD & Other Cellular Antigens: (http://www.ebioscience.com/resources/mouse-cd-
chart.htm#mouse-non-cd-chart) 
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9.1 Abbreviations 
Aaom1 Autoimmune aoritis in MRL mice 1 
AARDA American Autoimmune Related Diseases Association  
Adaz1 Anti-dsDNA antibody production in NZM 1 
AFLP Amplified fragment length polymorphism 
Agnm2 Autoimmune glomerulonephritis in MRL 2 
AID Autoimmune diseases 
AIL Advanced intercross line 
AIP Autoimmune pancreatitis 
ANA Anti-nuclear antibody 
Anti-ssDNA Anti-single stranded DNA 
Anti-dsDNA Anti-double stranded DNA 
APC-anti Alkaline Phosphate Conjugated antibody 
APC Antigen presenting cell 
ARE Antioxidant response element  
B10.Q C57BL/10 strain with H2q haplotype of MHC 
BCR B cell receptor 
bp Base pair 
BUN Blood urea nitrogen 
Cag A Cytotoxin-associated gene A 
CA-II Carbonic anhydrase II  
CCP Cyclic citrullinated peptides 
CD Cluster of differentiation 
Cd19 CD19 antigen 
Cd4 CD4 antigen 
Cd69 CD69 antigen 
Cd8a CD8 antigen, alpha chain 
Cd8b1 CD8 antigen, beta chain 1 
Cdcs10 Cytokine deficiency colitis susceptibility 10 
cDNA Complementary DNA 
CFTR Cystic Fibrosis Transmembrane Regulator 
Chr. Chromosome 
 Abbreviations  
II 
 
 
CI Confidential interval 
CIA Collagen-induced arthritis 
Cia2 Collagen-induced arthritis QTL 2 
Cia3 Collagen-induced arthritis QTL 3 
Cia4 Collagen-induced arthritis QTL 4 
Cia6 Collagen-induced arthritis QTL 6 
Cia7 Collagen-induced arthritis 7 
Clec4a2 C-type lectin domain family 4,member a2 
cM Centi Morgan 
CNS Central nervous system  
CP Chronic pancreatitis  
CT Computerized tomography  
CTLA-4 Cytotoxic T-lymphocyte antigen 4  
CTRC Chymotrypsinogen C 
Cypr5 Cytokine production 5 QTL 
Dbm1 Diabetes modifier 1 QTL 
DCIR Dendritic cell immunoreceptor 
DCs Dendritic cells  
DNA Deoxyribonucleic acid 
E. Coli Escherichia coli 
Eae21 Experimental allergic encephalomyelitis susceptibility 21  
Eae26 Experimental allergic encephalomyelitis susceptibility 26 
Eae33 Experimental allergic encephalomyelitis susceptibility 33  
EBA Epidermolysis bullosa acquisita 
ELISA Enzyme-linked immunosorbent assay 
F Filial generation 
F2 F2 intercross 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
Fig. Figure 
FITC Fluorescein isothiocyanate conjugated 
FoxP3 Forkhead box p3 
FWB FACS Wash Buffer  
 Abbreviations  
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g Gram 
G1  First generation 
G4  Fourth generation 
GBS Guillain-Barré syndrome 
GEL Granulocytic epithelial lesion  
GN Glomerulonephritis  
H&E Haematoxylin and eosin  
HLA Human leukocyte antigen, 
hnRNPs Heterogeneous nuclear ribonucleoproteins  
HPF High power field 
HS Heterogeneous stock 
IBD Inflammatory bowel disease  
Ibdq2 Inflammatory bowel disease QTL 2 
IC Ag Intracellular antigens 
ICDC International consensus diagnostic criteria  
IDCP Idiopathic duct-centric pancreatitis 
Idd27 Insulin dependent diabetes susceptibility 
IDDM Insulin dependent diabetes mellitus  
INF-k Interferon kappa 
Ifnk Interferon kappa gene  
IFN-γ Interferon gamma 
IFN-γ R Interferon gamma receptor 
Ig Immunoglobulin 
IgG4 Immunoglobulin G4 
IgG4 RsD IgG4-related sclerosing disease 
IgG4-RD IgG4-related disease 
IgG4-RSD IgG4- related systemic disease  
Igsf6 Immunoglobulin super family 
IL10 Interleukin 10 
Il12rb2  Interleukin 12 receptor, beta 2 
Il17b Interleukin 17b  
Il17ra Interleukin 17 receptor A gene 
Il18bp Interleukin 18 binding protein 
 Abbreviations  
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Il1f10 Interleukin 1 family, member 10 
Il1f5 Interleukin 1 family, member 5 
Il1f6 Interleukin 1 family, member 6, 
Il1f8 Interleukin 1 family, member 8 
Il1f9 Interleukin 1 family, member 9 
Il1rn Interleukin 1 receptor antagonist 
IL2 Interleukin 2  
Il23r  Interleukin 23 receptor 
Il2ra Interleukin 2 receptor, alpha chain 
IL4 Interleukin 4 
Il4ppq IL4 producing potential QTL 
Il4ra Interleukin 4 receptor, alpha gene 
IL7 Interleukin 7 
Irak2 Interleukin-1 receptor- associated kinase 2 
ITP Idiopathic Thrombocytopenic Purpura 
IVIg Intravenous immunoglobulin  
IVIg Intravenous immunoglobulin  
Lat Linker for activation of T cells 
LF Lactoferrin  
LOD Logarithm of the odds  
Log p Logarithm of P value 
LP-BM5 Murine leukemia virus 
LPSP Lymphoplasmacytic sclerosing pancreatitis  
LT Lymphotoxin  
Ltbr lymphotoxin B receptor gene 
Lxw1 Lupus BXSB x NZW 1 
m milli (10-3) 
M Molar (mol/dm3) 
mAb  Monoclonal antibody 
MAX Maximum 
Mbp Million base pairs/mega base pairs 
mg/ml Milligrams per milliliter  
MHC Major histocompatibility complex 
 Abbreviations  
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min Minute  
mM Millimolar 
MRI Magnetic Resonance Imaging 
mRNA Messenger ribonucleic acid 
MS Multiple sclerosis 
mtDNA Mitochondrial DNA 
n Nano (10-9) 
N2 N2 backcross generation 
Nbwa2 NZB and NZW autoimmunity 2 QTL 
NIH National Institutes of Health  
Nrf2 Nuclear factor, erythroid derived 2, like 2 gene 
nTx neonatal thymectomy 
P P value(s) 
PAIL Partial advanced Intercross lines  
PBS Phosphate buffered saline 
PE Phycoerythrin 
PerCP-Cy5.5 Peridinin Chlorophyll protein -Cy5.5 
PGIA Proteoglycan-induced arthritis  
Pgia27 Proteoglycan induced arthritis 27 
poly I:C Polyinosinic,polycytidylic acid 
PPARγ Peroxisome proliferator-activated receptor γ  
PRSS1 Protease serine 1 
PRSS2 Protease serine 2 
Psds1 Psoriasis-like skin disease severity 1 
PSTI Pancreatic secretory trypsin inhibitor 
Ptf1a Pancreas specific transcription factor, 1a 
QT  Quantitative trait 
QTG Quantitative trait gene 
QTL Quantitative trait loci 
RA Rheumatoid arthritis 
RF Rheumatoid factor 
RIL Recombination inbred lines  
RNA Ribonucleic acid 
 Abbreviations  
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rpm  Rounds per minute 
Sec. Second 
SjS Sjogren syndrome 
SLE Systemic Lupus Erythematosus  
Sle2 Systemic lupus erythmatosus susceptibility 2 
SNP Single nucleotide polymorphism  
SPINK1 Serine protease inhibitor Kazal type1 
Ssb Sjogren syndrome antigen B 
TCR T cell receptor 
Th1 T helper 1  
Th17 Interleukin 17 
Th2 T helper 2 
Thcr T helper cell response QTL 
Tlf T lymphocyte fraction 
Tregs Regulatory T cells  
UBR2 Ubiquitin Protein Ligase E3 Component N-Recognin 2 
Ubr3 Ubiquitin protein ligase E3 component n-recognin 3  
µ Micro (10-6) 
µl Microliter 
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